{"content":"<li class=\"n-box-item date-title\" data-end=\"1521172799\" data-start=\"1521086400\" data-txt=\"Monday, December 23, 2019\">Thursday, March 15, 2018</li><li class=\"n-box-item sa-box-item\" data-id=\"3339777\" data-ts=\"1521157486\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LITE\" target=\"_blank\">LITE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3339777-optical-component-firms-finish-lower-b-riley-gets-cautious\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Some optical component firms finish lower as B. Riley gets cautious</a></h4><ul>   <li>B. Riley FBR's Dave Kang spent two day days at the Optical Fiber Communication conference, and comes away incrementally more cautious on the component sector.</li>    <li>Aside from Lumentum (NASDAQ:<a href='https://seekingalpha.com/symbol/LITE' title='Lumentum Holdings Inc.'>LITE</a>), curretly with a deal to acquire Oclaro (NASDAQ:<a href='https://seekingalpha.com/symbol/OCLR' title='Oclaro, Inc.'>OCLR</a>), most U.S.-based vendors are cautious on growth prospects in China this year, he writes, and Japanese vendors were more optimistic than those in the U.S. --though that doesn't yet mean Japanese firms are taking share from American companies. (h/t Bloomberg)</li>    <li>Kang has a Buy rating on Lumentum, but is Neutral on Applied Optoelectronics (NASDAQ:<a href='https://seekingalpha.com/symbol/AAOI' title='Applied Optoelectronics, Inc.'>AAOI</a>), which <font color='red'>slid 8%</font> during the session today. He's also Neutral on Finisar (NASDAQ:<a href='https://seekingalpha.com/symbol/FNSR' title='Finisar Corporation'>FNSR</a>), which <font color='red'>declined 6.4%</font> and is currently the subject of heavy speculation about its M&amp;A prospects.</li>    <li>Lumentum <font color='red'>declined 2.7%</font> today; Oclaro <font color='red'>fell 1.4%</font>. Meanwhile NeoPhotonics (NYSE:<a href='https://seekingalpha.com/symbol/NPTN' title='NeoPhotonics Corporation'>NPTN</a>) <font color='green'>rose 2%</font> and II-VI (NASDAQ:<a href='https://seekingalpha.com/symbol/IIVI' title='II-VI Incorporated'>IIVI</a>) closed <font color='green'>up 1.1%</font>.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3338390-analysts-challenges-finisar-lumentum-oclaro-deal\" target=\"_blank\">Analysts: Challenges for Finisar in Lumentum-Oclaro deal</a> (Mar. 12 2018)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3338158-finisar-marks-worst-day-months-analysts-process-gloom\" target=\"_blank\">Finisar marks worst day in months as analysts process gloom</a> (Mar. 09 2018)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3339777\" data-linked=\"Some optical component firms finish lower as B. Riley gets cautious\" data-tweet=\"$LITE $LITE $OCLR - Some optical component firms finish lower as B. Riley gets cautious https://seekingalpha.com/news/3339777-optical-component-firms-finish-lower-b-riley-gets-cautious?source=tweet\" data-url=\"https://seekingalpha.com/news/3339777-optical-component-firms-finish-lower-b-riley-gets-cautious\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:44 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>40&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3339774\" data-ts=\"1521155519\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CRSP\" target=\"_blank\">CRSP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3339774-crisprplus-1_9-guggenheim-gets-bullish-on-car-t-approach\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Crispr +1.9% as Guggenheim gets bullish on CAR-T approach</a></h4><ul>   <li>Crispr Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/CRSP' title='CRISPR Therapeutics'>CRSP</a>) is <font color='green'>up 1.9%</font> after hours after getting a bullish price target from Guggenheim.</li>    <li>The firm boosted its target to a Street-high $85 from $35, pointing to a \"potentially best-in-class\" allogeneic CAR-T approach that may be disruptive to immuno-oncology.</li>    <li>The allogeneic approach uses donor cells for CAR-T rather than a patient's own, and are currently approved only for blood cancers, but Guggenheim is looking to the possibility that such donor cells could be used to attack solid tumors (and in particular kidney cancer).</li> </ul><div class=\"tiny-share-widget\" data-id=\"3339774\" data-linked=\"Crispr +1.9% as Guggenheim gets bullish on CAR-T approach\" data-tweet=\"$CRSP - Crispr +1.9% as Guggenheim gets bullish on CAR-T approach https://seekingalpha.com/news/3339774-crisprplus-1_9-guggenheim-gets-bullish-on-car-t-approach?source=tweet\" data-url=\"https://seekingalpha.com/news/3339774-crisprplus-1_9-guggenheim-gets-bullish-on-car-t-approach\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:11 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>18&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3339768\" data-ts=\"1521152693\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PRPL\" target=\"_blank\">PRPL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3339768-purpleminus-12_1-after-earnings-ceo-departure\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Purple -12.1% after earnings, CEO departure</a></h4><ul>   <li>Along with <a href=\"https://seekingalpha.com/news/3339733-purple-innovation-reports-q4-results\" target=\"_blank\">earnings today</a>, Purple Innovation (NASDAQ:<a href='https://seekingalpha.com/symbol/PRPL' title='Purple Innovation, Inc.'>PRPL</a>) announced its chief executive has <a href=\"https://seekingalpha.com/pr/17103940-purple-innovation-announces-ceo-departure\" target=\"_blank\">departed for other opportunities</a>.</li>    <li>Shares are <font color='red'>down 12.1%</font> postmarket.</li>    <li>CEO Sam Bernards has exited, and co-founder and Chairman Terry Pearce will serve as interim CEO during a replacement search. The company will use an executive search firm.</li>    <li>\"Under Sam's leadership, we dramatically expanded our sales, operations and brand awareness, strengthened our executive team, and completed our transition to a public company,\" Pearce says.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3339768\" data-linked=\"Purple -12.1% after earnings, CEO departure\" data-tweet=\"$PRPL - Purple -12.1% after earnings, CEO departure https://seekingalpha.com/news/3339768-purpleminus-12_1-after-earnings-ceo-departure?source=tweet\" data-url=\"https://seekingalpha.com/news/3339768-purpleminus-12_1-after-earnings-ceo-departure\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:24 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3339753\" data-ts=\"1521149861\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMRS\" target=\"_blank\">AMRS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3339753-after-hours-gainers-losers-3-15-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After Hours Gainers / Losers (3/15/2018)</a></h4><ul>     <li><b>Top gainers:</b> <a href='https://seekingalpha.com/symbol/AMRS' title='Amyris, Inc.'>AMRS</a> <font color='green'>+19.7%</font>. <a href='https://seekingalpha.com/symbol/KODK' title='Eastman Kodak Co.'>KODK</a> <font color='green'>+10.1%</font>. <a href='https://seekingalpha.com/symbol/KEYW' title='KEYW Holding'>KEYW</a> <font color='green'>+9.7%</font>. <a href='https://seekingalpha.com/symbol/CATB' title='Catabasis Pharmaceuticals'>CATB</a> <font color='green'>+5.7%</font>. <a href='https://seekingalpha.com/symbol/AUPH' title='Aurinia Pharmaceuticals Inc.'>AUPH</a> <font color='green'>+3.5%</font>.</li><li><b>Top losers:</b> <a href='https://seekingalpha.com/symbol/OSTK' title='Overstock.com, Inc.'>OSTK</a> <font color='red'>-8.2%</font>. <a href='https://seekingalpha.com/symbol/GEMP' title='Gemphire Therapeutics'>GEMP</a> <font color='red'>-5.2%</font>. <a href='https://seekingalpha.com/symbol/SABR' title='Sabre Corporation'>SABR</a> <font color='red'>-5.2%</font>. <a href='https://seekingalpha.com/symbol/W' title='Wayfair'>W</a> <font color='red'>-3.2%</font>. <a href='https://seekingalpha.com/symbol/CAAP' title='Corporacion America Airports SA'>CAAP</a> <font color='red'>-2.7%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3339753\" data-linked=\"After Hours Gainers / Losers (3/15/2018)\" data-tweet=\"$AMRS $AMRS $KODK - After Hours Gainers / Losers (3/15/2018) https://seekingalpha.com/news/3339753-after-hours-gainers-losers-3-15-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3339753-after-hours-gainers-losers-3-15-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:37 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3339737\" data-ts=\"1521147344\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ADBE\" target=\"_blank\">ADBE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3339737-adobes-upside-q2-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Adobe&#39;s upside Q2 guidance</a></h4><ul><li>        Adobe Systems (NASDAQ:<a href='https://seekingalpha.com/symbol/ADBE' title='Adobe Systems Incorporated'>ADBE</a>) <a href=\"https://wwwimages2.adobe.com/content/dam/acom/en/investor-relations/pdfs/51308102/bT4wmpT1QW3j3rm7.pdf\" target=\"_blank\">outlines</a> its upside Q2 guidance in the earnings call transcript.</li><li>               Q2 revenue is expected around $2.15B (consensus: $2.14B) with Digital Media revenue growth of 25% and net new Digital Media ARR at $330M. Digital Experience revenue growth expected at 15%.&nbsp;</li><li>                  EPS expected around $1.53 (consensus: $1.51).    </li><li>               Tax rate: 13% on GAAP basis and 11% non-GAAP.&nbsp;</li><li>               Adobe shares are&nbsp;<font color='green'>up 3.3%</font>&nbsp;aftermarket to $226.09.&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3339662-adobe-systems-beats-0_11-beats-revenue\" target=\"_blank\">Adobe Systems beats by $0.11, beats on revenue</a> (March 15)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3339691-adobe-plus-3_4-percent-q1-beats-30-percent-subscription-growth\" target=\"_blank\">Adobe +3.4% on Q1 beats, 30% Subscription growth</a> (March 15)</li></ul><div class=\"tiny-share-widget\" data-id=\"3339737\" data-linked=\"Adobe&#39;s upside Q2 guidance\" data-tweet=\"$ADBE - Adobe&#39;s upside Q2 guidance https://seekingalpha.com/news/3339737-adobes-upside-q2-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3339737-adobes-upside-q2-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:55 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3339723\" data-ts=\"1521146578\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JBL\" target=\"_blank\">JBL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3339723-jabilplus-3_4-on-q2-beats-in-line-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Jabil +3.4% on Q2 beats, in-line guidance</a></h4><ul><li>        Jabil (NYSE:<a href='https://seekingalpha.com/symbol/JBL' title='Jabil Inc.'>JBL</a>) shares&nbsp;<font color='green'>gain 3.4%</font>&nbsp;aftermarket on Q2 results that beat EPS and revenue estimates with 19.1% Y/Y revenue growth. In-line Q3 guidance has revenue from $4.75B to $5.05B (consensus: $4.82B) and EPS from $0.35 to $0.55 (consensus: $0.45).</li><li>               More Q3 guidance: Diversified Manufacturing Services revenue is expected to grow 10% on the year. Electronics Manufacturing Services is expected to post an 8% growth.&nbsp;</li><li>               Key metrics: Diversified Manufacturing Services revenue growth, 38%; Electronics Manufacturing Services growth, 7%; cash and equivalents, $940.8M; total liabilities, $9.2B; SG&amp;A, $243.9M; R&amp;D, $8.3M.&nbsp;</li><li>               <a href=\"https://seekingalpha.com/pr/17103959-jabil-posts-second-quarter-results\" target=\"_blank\">Press release</a>&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3339660-jabil-beats-0_04-beats-revenue\" target=\"_blank\">Jabil beats by $0.04, beats on revenue</a> (March 15)</li></ul><div class=\"tiny-share-widget\" data-id=\"3339723\" data-linked=\"Jabil +3.4% on Q2 beats, in-line guidance\" data-tweet=\"$JBL - Jabil +3.4% on Q2 beats, in-line guidance https://seekingalpha.com/news/3339723-jabilplus-3_4-on-q2-beats-in-line-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3339723-jabilplus-3_4-on-q2-beats-in-line-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:42 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3339697\" data-ts=\"1521145826\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VIVE\" target=\"_blank\">VIVE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3339697-viveve-medical-misses-0_06-revenue-in-line\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Viveve Medical misses by $0.06,  revenue in-line</a></h4><ul><li>Viveve Medical (NASDAQ:<a href='https://seekingalpha.com/symbol/VIVE' title='Viveve Medical, Inc.'>VIVE</a>): Q4 EPS of -$0.53 <font color='red'>misses by $0.06</font>.</li><li>Revenue of $5.1M (+108.2% Y/Y) in-line.</li><li>Shares <font color='green'>+7.54%</font>.</li><li><a href='https://seekingalpha.com/pr/17103925-viveve-reports-fourth-quarter-full-year-2017-financial-results'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3339697\" data-linked=\"Viveve Medical misses by $0.06,  revenue in-line\" data-tweet=\"$VIVE - Viveve Medical misses by $0.06, revenue in-line https://seekingalpha.com/news/3339697-viveve-medical-misses-0_06-revenue-in-line?source=tweet\" data-url=\"https://seekingalpha.com/news/3339697-viveve-medical-misses-0_06-revenue-in-line\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:30 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3339693\" data-ts=\"1521145760\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KODK\" target=\"_blank\">KODK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3339693-eastman-kodak-reports-q4-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Eastman Kodak reports Q4 results</a></h4><ul><li>Eastman Kodak (NYSE:<a href='https://seekingalpha.com/symbol/KODK' title='Eastman Kodak Co.'>KODK</a>): Q4 net income of $129M</li><li>Revenue of $414M (-4.2% Y/Y)</li><li>Shares <font color='green'>+15.1%</font>.</li><li><a href=\"https://seekingalpha.com/pr/17104012-kodak-reports-fourth-quarter-full-year-2017-financial-results\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3339693\" data-linked=\"Eastman Kodak reports Q4 results\" data-tweet=\"$KODK - Eastman Kodak reports Q4 results https://seekingalpha.com/news/3339693-eastman-kodak-reports-q4-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3339693-eastman-kodak-reports-q4-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:29 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3339691\" data-ts=\"1521145747\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ADBE\" target=\"_blank\">ADBE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3339691-adobeplus-3_4-on-q1-beats-30-subscription-growth\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Adobe +3.4% on Q1 beats, 30% Subscription growth</a></h4><ul><li>        Adobe Systems (NASDAQ:<a href='https://seekingalpha.com/symbol/ADBE' title='Adobe Systems Incorporated'>ADBE</a>)&nbsp;<font color='green'>gains 3.4%</font>&nbsp;aftermarket on Q1 results that beat estimates with a 24% Y/Y revenue growth.</li><li>               Revenue breakdown: Subscription, $1.79B (+30% Y/Y); Product, $171.6M (-6%); Services and support, $113.98M (-0.3%).&nbsp;</li><li>               Segment revenue: Digital Media sales totaled $1.46B with Creative at $1.23B and Document Cloud at $231M. &nbsp;Digital Experience revenue was $554M (+16%).&nbsp;</li><li>               Segment Annualized Recurring Revenue: Digital Media ARR grew to $5.72B (up $336M Q/Q). Creative ARR reached $5.07B and Document Cloud ARR grew to $647M.&nbsp;</li><li>               Key metrics: Cash flow from operations, $990M; deferred revenue, $2.57B (+25% Y/Y); share repurchase, 1.6M shares with $301M in cash returned to shareholders; total operating expenses, $1.1B; cash and equivalents, $2.67B; long-term debt, $1.87B.&nbsp;</li><li>                  Earnings call is scheduled for 5 PM ET with webcast available <a href=\"https://www.adobe.com/investor-relations.html\" target=\"_blank\">here</a>.    </li><li>               <a href=\"https://seekingalpha.com/pr/17103958-adobe-achieves-record-revenue\" target=\"_blank\">Press release</a>&nbsp; &nbsp;&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3339662-adobe-systems-beats-0_11-beats-revenue\" target=\"_blank\">Adobe Systems beats by $0.11, beats on revenue</a> (March 15)</li></ul><div class=\"tiny-share-widget\" data-id=\"3339691\" data-linked=\"Adobe +3.4% on Q1 beats, 30% Subscription growth\" data-tweet=\"$ADBE - Adobe +3.4% on Q1 beats, 30% Subscription growth https://seekingalpha.com/news/3339691-adobeplus-3_4-on-q1-beats-30-subscription-growth?source=tweet\" data-url=\"https://seekingalpha.com/news/3339691-adobeplus-3_4-on-q1-beats-30-subscription-growth\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:29 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3339662\" data-ts=\"1521144516\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ADBE\" target=\"_blank\">ADBE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3339662-adobe-systems-beats-0_11-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Adobe Systems beats by $0.11, beats on revenue</a></h4><ul><li>Adobe Systems (NASDAQ:<a href='https://seekingalpha.com/symbol/ADBE' title='Adobe Systems Incorporated'>ADBE</a>): Q1 EPS of $1.55 <font color='green'>beats by $0.11</font>.</li><li>Revenue of $2.08B (+23.8% Y/Y) <font color='green'>beats by $30M</font>.</li><li>Shares <font color='green'>+1.25%</font>.</li><li><a href='https://seekingalpha.com/pr/17103958-adobe-achieves-record-revenue'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3339662\" data-linked=\"Adobe Systems beats by $0.11, beats on revenue\" data-tweet=\"$ADBE - Adobe Systems beats by $0.11, beats on revenue https://seekingalpha.com/news/3339662-adobe-systems-beats-0_11-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3339662-adobe-systems-beats-0_11-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:08 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3339651\" data-ts=\"1521144218\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMRS\" target=\"_blank\">AMRS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3339651-amyris-beats-0_54-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Amyris beats by $0.54, beats on revenue</a></h4><ul><li>Amyris (NASDAQ:<a href='https://seekingalpha.com/symbol/AMRS' title='Amyris, Inc.'>AMRS</a>): Q4 EPS of $0.61 <font color='green'>beats by $0.54</font>.</li><li>Revenue of $80.59M (+262.4% Y/Y) <font color='green'>beats by $12.45M</font>.</li><li>Shares <font color='green'>+10%</font>.</li><li><a href='https://seekingalpha.com/pr/17103890-amyris-reports-another-strong-quarter-solid-operating-performance-2017-revenue-143_4-million'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3339651\" data-linked=\"Amyris beats by $0.54, beats on revenue\" data-tweet=\"$AMRS - Amyris beats by $0.54, beats on revenue https://seekingalpha.com/news/3339651-amyris-beats-0_54-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3339651-amyris-beats-0_54-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:03 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3339638\" data-ts=\"1521142528\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/INTC\" target=\"_blank\">INTC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3339638-intels-new-processors-come-spectre-fix\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Intel&#39;s new processors come with a Spectre fix</a></h4><ul><li>        Intel (NASDAQ:<a href='https://seekingalpha.com/symbol/INTC' title='Intel Corporation'>INTC</a>) <a href=\"https://www.theverge.com/2018/3/15/17123610/intel-new-processors-protection-spectre-vulnerability\" target=\"_blank\">says</a> the upcoming Cascade Lake Xeon processors will include &ldquo;redesigned parts of the processor to introduce new levels of protection through partitioning&rdquo; to protect against variants of the Spectre chip flaw. &nbsp;</li><li>        The portioning will also appear in the 8<sup>th</sup> gen Intel Core processors.</li><li>               Both of the new processors will ship in 2H18.&nbsp;</li><li>               Don&rsquo;t want to upgrade your Intel CPU? Keep up with the firmware updates (now available for 100% of products launched within the past five years) for Spectre protection.&nbsp;</li><li>               Intel shares are&nbsp;<font color='red'>down 1.6%</font>&nbsp;to $51.&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3339479-intel-declares-0_30-dividend\" target=\"_blank\">Intel declares $0.30 dividend</a> (March 15)</li></ul><div class=\"tiny-share-widget\" data-id=\"3339638\" data-linked=\"Intel&#39;s new processors come with a Spectre fix\" data-tweet=\"$INTC - Intel&#39;s new processors come with a Spectre fix https://seekingalpha.com/news/3339638-intels-new-processors-come-spectre-fix?source=tweet\" data-url=\"https://seekingalpha.com/news/3339638-intels-new-processors-come-spectre-fix\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:35 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>26&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3339631\" data-ts=\"1521140597\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EPD\" target=\"_blank\">EPD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3339631-enterprise-products-says-ferc-tax-ruling-not-seen-material-impact\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Enterprise Products says FERC tax ruling not seen having material impact</a></h4><ul>     <li>Enterprise Products Partners (<a href='https://seekingalpha.com/symbol/EPD' title='Enterprise Products Partners L.P'>EPD</a> <font color='red'>-2%</font>) trims earlier losses of as much as 9% after saying today's FERC policy revision is <a href=\"https://seekingalpha.com/pr/17103811-ferc-policy-revision-material-impact-enterprise-financial-results\" target=\"_blank\">not expected to have a material impact</a> to its earnings and cash flow.</li>     <li>The FERC <a href=\"https://seekingalpha.com/news/3339594-mlps-suffer-sharp-losses-ferc-nixes-income-tax-allowance-cost-recovery\" target=\"_blank\">said earlier today</a> that it would revise its earlier policy so that it no longer allows interstate pipelines owned by MLPs to recover an income tax allowance in the cost of service.</li>     <li>\"We do not expect the revisions to the FERC's policy on the recovery of income taxes to  materially impact our earnings and cash flow,\" EPD says. \"The cost-based  tariff rates that are in effect for all of our interstate pipelines are based on a cost of service for those pipelines whereby the disallowance for the recovery of an income tax allowance will not have a material effect, if any, to the posted tariffs.\"</li></ul><div class=\"tiny-share-widget\" data-id=\"3339631\" data-linked=\"Enterprise Products says FERC tax ruling not seen having material impact\" data-tweet=\"$EPD - Enterprise Products says FERC tax ruling not seen having material impact https://seekingalpha.com/news/3339631-enterprise-products-says-ferc-tax-ruling-not-seen-material-impact?source=tweet\" data-url=\"https://seekingalpha.com/news/3339631-enterprise-products-says-ferc-tax-ruling-not-seen-material-impact\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:03 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3339629\" data-ts=\"1521140118\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ISNS\" target=\"_blank\">ISNS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3339629-technology-top-gainers-losers-of-2_55-pm-3-15-18\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Technology - Top Gainers / Losers as of 2.55 pm (3/15/18)</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/ISNS' title='Image Sensing Systems, Inc.'>ISNS</a> <font color='green'>+36%</font>. COGT <font color='green'>+17%</font>. <a href='https://seekingalpha.com/symbol/RUBI' title='The Rubicon Project, Inc.'>RUBI</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/PTI' title='Proteostasis Therapeutics'>PTI</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/ELTK' title='Eltek Ltd.'>ELTK</a> <font color='green'>+12%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/ASUR' title='Asure Software, Inc.'>ASUR</a> <font color='red'>-19%</font>. <a href='https://seekingalpha.com/symbol/BITA' title='Bitauto Holdings Limited'>BITA</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/NETE' title='Net Element International, Inc.'>NETE</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/GRVY' title='GRAVITY Co., Ltd. - American depositary shares, each representing one'>GRVY</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/CPAH' title='CounterPath Corporation'>CPAH</a> <font color='red'>-8%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3339629\" data-linked=\"Technology - Top Gainers / Losers as of 2.55 pm (3/15/18)\" data-tweet=\"$ISNS $ISNS $FLNT - Technology - Top Gainers / Losers as of 2.55 pm (3/15/18) https://seekingalpha.com/news/3339629-technology-top-gainers-losers-of-2_55-pm-3-15-18?source=tweet\" data-url=\"https://seekingalpha.com/news/3339629-technology-top-gainers-losers-of-2_55-pm-3-15-18\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:55 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3339622\" data-ts=\"1521138205\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WIT\" target=\"_blank\">WIT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3339622-wipro-invests-2m-for-minority-stake-in-ai-startup\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Wipro invests $2M for minority stake in AI startup</a></h4><ul><li>Wipro (NYSE:<a href='https://seekingalpha.com/symbol/WIT' title='Wipro Limited'>WIT</a>) <a href=\"https://www.vccircle.com/wipro-picks-up-minority-stake-in-us-based-startup-avaamo/\" target=\"_blank\">picks up a minority stake</a> in AI startup Avaamo for $2.02M.</li><li>Wipro will make additional investments through convertible note conversions that will take the total investment up to $3.02M and a stake of under 20% on a fully diluted basis.</li><li>Avaamo provides an AI enterprise bot platform that speeds up the deployment of enterprise bots for employees and customers.</li><li>Wipro shares are&nbsp;<font color='green'>up 0.9%</font>&nbsp;to $5.68.</li></ul><div class=\"tiny-share-widget\" data-id=\"3339622\" data-linked=\"Wipro invests $2M for minority stake in AI startup\" data-tweet=\"$WIT - Wipro invests $2M for minority stake in AI startup https://seekingalpha.com/news/3339622-wipro-invests-2m-for-minority-stake-in-ai-startup?source=tweet\" data-url=\"https://seekingalpha.com/news/3339622-wipro-invests-2m-for-minority-stake-in-ai-startup\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:23 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3339616\" data-ts=\"1521138160\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CME\" target=\"_blank\">CME</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3339616-cme-considering-bid-for-nex-group\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CME considering a bid for NEX Group</a></h4><ul><li>CME Group's<a href=\"https://www.bloomberg.com/news/articles/2018-03-15/cme-is-said-to-consider-bidding-for-michael-spencer-s-nex-group\" target=\"_blank\"> potential offer</a> for NEX would give the futures trading giant access into the inter-dealer brokerage business.</li><li>The London-listed NEX Group Plc, formerly ICAP, has a $3.5B market cap, and the two companies are having preliminary discussions right now.</li><li>Both stocks are up today, with <a href='https://seekingalpha.com/symbol/CME' title='CME Group Inc.'>CME</a> <font color='green'>+1.4%</font>&nbsp;and NEX <font color='green'>+2.2%</font>&nbsp;at London close.</li></ul><div class=\"tiny-share-widget\" data-id=\"3339616\" data-linked=\"CME considering a bid for NEX Group\" data-tweet=\"$CME - CME considering a bid for NEX Group https://seekingalpha.com/news/3339616-cme-considering-bid-for-nex-group?source=tweet\" data-url=\"https://seekingalpha.com/news/3339616-cme-considering-bid-for-nex-group\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:22 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3339613\" data-ts=\"1521136880\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OSN\" target=\"_blank\">OSN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3339613-energy-materials-top-gainers-losers-of-2-00-pm-3-15-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energy/Materials - Top Gainers / Losers as of 2:00 pm (3/15/2018)</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/OSN' title='Ossen Innovation Co., Ltd.'>OSN</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/SMTS' title='Sierra Metals, Inc.'>SMTS</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/DELT' title='Delta Technology Holdings Limited'>DELT</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/HNRG' title='Hallador Energy Co'>HNRG</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/SDPI' title='Superior Drilling Products, Inc.'>SDPI</a> <font color='green'>+6%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/YTEN' title='Yield10 Bioscience, Inc.'>YTEN</a> <font color='red'>-28%</font>. <a href='https://seekingalpha.com/symbol/RKDA' title='Arcadia Biosciences'>RKDA</a> <font color='red'>-23%</font>. <a href='https://seekingalpha.com/symbol/SND' title='Smart Sand'>SND</a> <font color='red'>-17%</font>. <a href='https://seekingalpha.com/symbol/EEP' title='Enbridge Energy Partners L.P.'>EEP</a> <font color='red'>-16%</font>. <a href='https://seekingalpha.com/symbol/EEQ' title='Enbridge Energy Management, L.L.C.'>EEQ</a> <font color='red'>-15%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3339613\" data-linked=\"Energy/Materials - Top Gainers / Losers as of 2:00 pm (3/15/2018)\" data-tweet=\"$OSN $OSN $SMTS - Energy/Materials - Top Gainers / Losers as of 2:00 pm (3/15/2018) https://seekingalpha.com/news/3339613-energy-materials-top-gainers-losers-of-2-00-pm-3-15-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3339613-energy-materials-top-gainers-losers-of-2-00-pm-3-15-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:01 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3339609\" data-ts=\"1521136193\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MDXG\" target=\"_blank\">MDXG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3339609-mimedx-sees-q1-sales-above-92m-investors-unmoved-shares-down-4\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">MiMedx sees Q1 sales above $92M; investors unmoved, shares down 4%</a></h4><ul><li>MiMedx (<a href='https://seekingalpha.com/symbol/MDXG' title='MiMedx Group Inc.'>OTC:MDXG</a> <font color='red'>-3.9%</font>) projects Q1 sales of more than $92M, at least 4% above consensus of $88.6M. It reiterates its 2018 sales guidance of $383M - 387M (consensus is $384.9M).</li><li>Investors remain wary of the outcome of an investigation into its business practices.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3334664-mimedx-denies-claims-bloomberg-report-shares-minus-1_6-percent\" target=\"_blank\">MiMedx denies claims in Bloomberg report; shares -1.6%</a> (Feb. 27)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3332273-mimedx-postpones-release-q4-results-internal-investigation-sales-distribution-practices\" target=\"_blank\">MiMedx postpones release of Q4 results on internal investigation into sales/distribution practices; shares halted</a> (Feb. 20)</li></ul><div class=\"tiny-share-widget\" data-id=\"3339609\" data-linked=\"MiMedx sees Q1 sales above $92M; investors unmoved, shares down 4%\" data-tweet=\"$MDXG - MiMedx sees Q1 sales above $92M; investors unmoved, shares down 4% https://seekingalpha.com/news/3339609-mimedx-sees-q1-sales-above-92m-investors-unmoved-shares-down-4?source=tweet\" data-url=\"https://seekingalpha.com/news/3339609-mimedx-sees-q1-sales-above-92m-investors-unmoved-shares-down-4\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:49 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>33&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3339610\" data-ts=\"1521136047\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LCUT\" target=\"_blank\">LCUT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3339610-on-lifetime-brandss-q4\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">More on Lifetime Brands&#39;s Q4</a></h4><ul><li>Lifetime Brands (<a href='https://seekingalpha.com/symbol/LCUT' title='Lifetime Brands, Inc.'>LCUT</a> <font color='red'>-9.1%</font>)&nbsp;reports revenue growth of 6.5% in <a href=\"https://seekingalpha.com/pr/17102894-lifetime-brands-inc-reports-fourth-quarter-2017-financial-results\" target=\"_blank\">Q4</a>, on a constant currency basis.</li><li>Sales break-up: U.S. wholesale: $143.33M (-8.3%, -8.4% on a constant currency basis); International: $38.33M (+9.4%, +2.4% on a constant currency basis); Retail direct: $7.61M (-5.5%, -5.5% on a constant currency basis).</li><li>Gross margin rate improved 20 bps to 39%.</li><li>Adjusted EBITDA margin rate down 230 bps to 10.5%.</li><li>Operating margin rate squeezed 540 bps to 5.9%.</li><li>Inventory -2.1% Y/Y to $132.44M.</li></ul><div class=\"tiny-share-widget\" data-id=\"3339610\" data-linked=\"More on Lifetime Brands&#39;s Q4\" data-tweet=\"$LCUT - More on Lifetime Brands&#39;s Q4 https://seekingalpha.com/news/3339610-on-lifetime-brandss-q4?source=tweet\" data-url=\"https://seekingalpha.com/news/3339610-on-lifetime-brandss-q4\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:47 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3339608\" data-ts=\"1521135744\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PHIO\" target=\"_blank\">PHIO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3339608-rxi-pharma-adds-to-rally-up-31\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">RXi Pharma adds to rally, up 31%</a></h4><ul><li>Thinly traded nano cap RXi Pharmaceuticals (RXII <font color='green'>+31%</font>) is up on a 13x surge in volume. Shares have more than doubled since last week as shares attempt to break a long-term downtrend.</li><li>No particular news accounts for the action. The company's lead candidate is RXI-109, a self-delivering RNAi therapeutic in Phase 2 development for the reducing dermal scarring following surgery and in Phase 1/2 development for reducing the progression of subretinal fibrosis in patients with advanced neovascular age-related macular degeneration.</li><li>In January, it announced a revamped strategy to extend its cash runway while accelerating development of candidates RXI-762 and RXI-804.</li><li>At the end of September 2017, it had ~$5.4M in unrestricted cash and operations consumed $7.3M over the first three quarters of 2017 so additional capital will be needed.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3322876-rxi-pharma-announces-business-strategy-focus-immuno-oncology-programs-accelerate-growth\" target=\"_blank\">RXi Pharma announces business strategy to focus on immuno-oncology programs to accelerate growth</a> (Jan. 16)</li></ul><div class=\"tiny-share-widget\" data-id=\"3339608\" data-linked=\"RXi Pharma adds to rally, up 31%\" data-tweet=\"$PHIO - RXi Pharma adds to rally, up 31% https://seekingalpha.com/news/3339608-rxi-pharma-adds-to-rally-up-31?source=tweet\" data-url=\"https://seekingalpha.com/news/3339608-rxi-pharma-adds-to-rally-up-31\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:42 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3339607\" data-ts=\"1521135691\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NXPI\" target=\"_blank\">NXPI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3339607-deutsche-bank-resumes-nxp-semiconductors-after-quashed-broadcom-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Deutsche Bank resumes NXP Semiconductors after quashed Broadcom deal</a></h4><ul><li>        Deutsche Bank resumes coverage on NXP Semiconductors (<a href='https://seekingalpha.com/symbol/NXPI' title='NXP Semiconductors'>NXPI</a>) with a Hold rating and $127.50 price target, a 4% upside to yesterday&rsquo;s close. &nbsp;</li><li>        Firm says Broadcom&rsquo;s (<a href='https://seekingalpha.com/symbol/AVGO' title='Broadcom Limited'>AVGO</a> <font color='green'>+3%</font>) quashed takeover of Qualcomm (<a href='https://seekingalpha.com/symbol/QCOM' title='Qualcomm Inc.'>QCOM</a> <font color='red'>-0.3%</font>) makes it more likely that Qualcomm will complete the NXP acquisition.</li><li>               The only outstanding regulatory approval remaining is China&rsquo;s MOFCOM and the firm assumes that will happen given the prior regulatory approvals.&nbsp;</li><li>               Deutsche thinks the deal will close within weeks of receiving the approval and Qualcomm could make comments on its Q1 earnings call.&nbsp;</li><li>               Source: Briefing.com.&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3338543-trump-issues-order-block-broadcom-takeover-qualcomm\" target=\"_blank\">Trump issues order to block Broadcom takeover of Qualcomm</a> (March 12)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3339002-broadcom-officially-withdraws-qualcomm-offer\" target=\"_blank\">Broadcom officially withdraws Qualcomm offer</a> (March 14)</li></ul><div class=\"tiny-share-widget\" data-id=\"3339607\" data-linked=\"Deutsche Bank resumes NXP Semiconductors after quashed Broadcom deal\" data-tweet=\"$NXPI $NXPI $AVGO - Deutsche Bank resumes NXP Semiconductors after quashed Broadcom deal https://seekingalpha.com/news/3339607-deutsche-bank-resumes-nxp-semiconductors-after-quashed-broadcom-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3339607-deutsche-bank-resumes-nxp-semiconductors-after-quashed-broadcom-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:41 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>32&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3339602\" data-ts=\"1521134971\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMZN\" target=\"_blank\">AMZN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3339602-cnbc-aws-planning-ready-to-use-corporate-training\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CNBC: AWS planning ready-to-use corporate training</a></h4><ul><li>Amazon (<a href='https://seekingalpha.com/symbol/AMZN' title='Amazon.com, Inc.'>AMZN</a> <font color='red'>-0.4%</font>) Web Services is considering a service that lets companies show training content to employees, according to <a href=\"https://www.cnbc.com/2018/03/15/amazon-aws-exploring-learning-management-space.html\" target=\"_blank\">CNBC sources</a>.</li><li>Ready-to-use services could help boost AWS market share in the cloud services market, where the company stands in the lead but has a slower growth rate than competitors Microsoft Azure and Google Cloud.</li><li>Amazon plans to build the system itself to customize the software.</li><li>Amazon currently offers online training programs for enterprise partners to train employees on how to use AWS. But the new products would allow the clients to manage any corporate training or learning program through Amazon.</li><li>Competitors in the space: Cornerstone OnDemand (<a href='https://seekingalpha.com/symbol/CSOD' title='Cornerstone OnDemand, Inc.'>CSOD</a> <font color='red'>-1.3%</font>), Oracle (<a href='https://seekingalpha.com/symbol/ORCL' title='Oracle Corporation'>ORCL</a> <font color='green'>+0.5%</font>), Workday (<a href='https://seekingalpha.com/symbol/WDAY' title='Workday'>WDAY</a> <font color='red'>-0.7%</font>), SAP (<a href='https://seekingalpha.com/symbol/SAP' title='SAP AG'>SAP</a> <font color='green'>+0.4%</font>), and Instructure.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3339356-revealed-amazons-numbers-prime-video\" target=\"_blank\">Revealed: Amazon's numbers on Prime Video</a> (March 15)</li></ul><div class=\"tiny-share-widget\" data-id=\"3339602\" data-linked=\"CNBC: AWS planning ready-to-use corporate training\" data-tweet=\"$AMZN $AMZN $CSOD - CNBC: AWS planning ready-to-use corporate training https://seekingalpha.com/news/3339602-cnbc-aws-planning-ready-to-use-corporate-training?source=tweet\" data-url=\"https://seekingalpha.com/news/3339602-cnbc-aws-planning-ready-to-use-corporate-training\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:29 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3339600\" data-ts=\"1521134144\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DXR\" target=\"_blank\">DXR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3339600-daxor-up-156-on-positive-blood-volume-analysis-data-in-heart-failure-patients\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Daxor up 156% on positive blood volume analysis data in heart failure patients</a></h4><ul><li>Thinly traded nano cap Daxor (<a href='https://seekingalpha.com/symbol/DXR' title='Daxor Corp'>DXR</a> <font color='green'>+156.4%</font>) rockets on a whopping 128x surge in volume in response to its <a href=\"https://seekingalpha.com/pr/17101685-new-data-showing-patient-care-individualized-daxor-s-precision-blood-volume-analysis-reduces\" target=\"_blank\">announcement </a>of real-world data that showed a significant benefit to heart failure patients from the use of blood volume analysis &#40;BVA&#41; performed on its <a href=\"http://www.daxor.com/bva-100/\" target=\"_blank\">BVA-100 </a>analyzer. The results were presented at the American College of Cardiology Scientific Session &amp; Expo in Orlando, FL.</li><li>In 245 heart failure patients who received individualized care guided by BVA, the 30-day all-cause mortality was 2.0%, 82% lower than 11.1% in the matched control population (p&lt;0.001), implying a 56% relative reduction in the risk of 30-day readmissions compared to conventionally managed patients.</li><li>The company says BVA enables clinicians to directly measure a patient's blood volume, a hallmark of heart failure, with 98% accuracy, adding that the data have significant implications for hospitals since they are penalized by Medicare for 30-day heart failure readmission rates if they are above average.</li></ul><div class=\"tiny-share-widget\" data-id=\"3339600\" data-linked=\"Daxor up 156% on positive blood volume analysis data in heart failure patients\" data-tweet=\"$DXR - Daxor up 156% on positive blood volume analysis data in heart failure patients https://seekingalpha.com/news/3339600-daxor-up-156-on-positive-blood-volume-analysis-data-in-heart-failure-patients?source=tweet\" data-url=\"https://seekingalpha.com/news/3339600-daxor-up-156-on-positive-blood-volume-analysis-data-in-heart-failure-patients\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:15 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3339596\" data-ts=\"1521133294\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SNAP\" target=\"_blank\">SNAP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3339596-snapminus-4_5-ad-draws-criticism-from-rihanna-company-apologizes\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Snap -4.5% as ad draws criticism from Rihanna; company apologizes</a></h4><ul>   <li>Snap (NYSE:<a href='https://seekingalpha.com/symbol/SNAP' title='Snap Inc.'>SNAP</a>) is <font color='red'>off 4.5%</font> today amid an ad controversy that's drawn criticism from Rihanna, subject of an ad that made light of a domestic-violence incident involving the pop star.</li>    <li>The company's <a href=\"http://variety.com/2018/digital/news/march-madness-how-to-watch-the-2018-ncaa-basketball-tournament-online-live-stream-1202725746/\" target=\"_blank\">\"Impossible Choices\" ad</a> for game <i>Would You Rather?</i> asked \"Would you rather slap Rihanna or punch Chris Brown?\" Brown pleaded guilty to felony assault connected to a 2009 incident when he repeated struck his then-girlfriend Rihanna during Grammy weekend.</li>    <li>The company apologized, saying the ad violated guidelines and was approved by mistake.</li>    <li>Rihanna has slammed the company in an Instagram story: \"I'd love to call it ignorance, but I know you ain't that dumb! You spent money to animate something that would intentionally bring shame to DV victims and made a joke of it! ... Shame on you. Throw the whole app-oligy away.\"</li>    <li>A decline in shares late last month was widely attributed in part to <a href=\"https://seekingalpha.com/news/3333441-snap-sliding-bears-include-moffettnathanson-kylie-jenner\" target=\"_blank\">criticism of Snapchat's redesign</a> by celebrity user Kylie Jenner.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3339596\" data-linked=\"Snap -4.5% as ad draws criticism from Rihanna; company apologizes\" data-tweet=\"$SNAP - Snap -4.5% as ad draws criticism from Rihanna; company apologizes https://seekingalpha.com/news/3339596-snapminus-4_5-ad-draws-criticism-from-rihanna-company-apologizes?source=tweet\" data-url=\"https://seekingalpha.com/news/3339596-snapminus-4_5-ad-draws-criticism-from-rihanna-company-apologizes\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:01 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>36&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3339597\" data-ts=\"1521133213\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CWAY\" target=\"_blank\">CWAY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3339597-financials-top-5-gainers-losers-of-1-00-pm-03-15-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Financials - Top 5 Gainers / Losers as of 1:00 PM (03/15/2018)</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/CWAY' title='Coastway Bancorp, Inc.'>CWAY</a> <font color='green'>+21%</font>. <a href='https://seekingalpha.com/symbol/CARV' title='Carver Bancorp, Inc.'>CARV</a> <font color='green'>+12%</font>.<a href='https://seekingalpha.com/symbol/OPHC' title='OptimumBank Holdings, Inc.'>OPHC</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/FSAM' title='Fifth Street Asset Management Inc.A'>OTCPK:FSAM</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/FNHC' title='FedNat Holding Company'>FNHC</a> <font color='green'>+5%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/ABDC' title='Alcentra Capital Corporation'>ABDC</a> <font color='red'>-19%</font>. <a href='https://seekingalpha.com/symbol/CWH' title='Camping World Holdings'>CWH</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/IMH' title='Impac Mortgage Holdings, Inc.'>IMH</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/WHLR' title='Wheeler Real Estate Investment Trust'>WHLR</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/KINS' title='Kingstone Companies Inc'>KINS</a> <font color='red'>-8%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3339597\" data-linked=\"Financials - Top 5 Gainers / Losers as of 1:00 PM (03/15/2018)\" data-tweet=\"$CWAY $CWAY $CARV - Financials - Top 5 Gainers / Losers as of 1:00 PM (03/15/2018) https://seekingalpha.com/news/3339597-financials-top-5-gainers-losers-of-1-00-pm-03-15-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3339597-financials-top-5-gainers-losers-of-1-00-pm-03-15-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3339594\" data-ts=\"1521132969\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EEP\" target=\"_blank\">EEP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3339594-mlps-suffer-sharp-losses-ferc-nixes-income-tax-allowance-cost-recovery\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">MLPs suffer sharp losses as FERC nixes income tax allowance cost recovery</a></h4><ul>     <li>Master limited partnerships tumble across the board after the Federal Energy Regulatory Commission announces it will <a href=\"https://www.ferc.gov/media/news-releases/2018/2018-1/03-15-18-G-2.asp#.WqqUtIIh2it\" target=\"_blank\">no longer allow MLPs to recover an income tax allowance</a> in cost of service rates.</li>     <li>MLPs slumping to 52-week lows include <a href='https://seekingalpha.com/symbol/EEP' title='Enbridge Energy Partners L.P.'>EEP</a> <font color='red'>-14.6%</font>, <a href='https://seekingalpha.com/symbol/WMB' title='Williams Companies Inc'>WMB</a> <font color='red'>-12%</font>, <a href='https://seekingalpha.com/symbol/TCP' title='TC PipeLines, LP'>TCP</a> <font color='red'>-11.4%</font>, <a href='https://seekingalpha.com/symbol/BPL' title='Buckeye Partners L.P.'>BPL</a> <font color='red'>-8.4%</font>, ETE <font color='red'>-8.1%</font>, ETP <font color='red'>-7%</font>, <a href='https://seekingalpha.com/symbol/SNMP' title='Sanchez Midstream Partners LP'>SNMP</a> <font color='red'>-6.6%</font>, <a href='https://seekingalpha.com/symbol/PAGP' title='Plains GP Holdings, LP'>PAGP</a> <font color='red'>-6.1%</font>, <a href='https://seekingalpha.com/symbol/VLP' title='Valero Energy Partners LP'>VLP</a> <font color='red'>-6%</font>, <a href='https://seekingalpha.com/symbol/BWP' title='Boardwalk Pipeline Partners, LP'>BWP</a> <font color='red'>-4.9%</font>, <a href='https://seekingalpha.com/symbol/SHLX' title='Shell Midstream Partners, LP'>SHLX</a> <font color='red'>-5.5%</font>, <a href='https://seekingalpha.com/symbol/ANDX' title='Andeavor Logistics LP'>ANDX</a> <font color='red'>-5.2%</font>, <a href='https://seekingalpha.com/symbol/DCP' title='DCP Midstream'>DCP</a> <font color='red'>-4.5%</font>.</li>     <li>Among other losers: <a href='https://seekingalpha.com/symbol/EPD' title='Enterprise Products Partners L.P'>EPD</a> <font color='red'>-4%</font>, <a href='https://seekingalpha.com/symbol/WPZ' title='Williams Partners L.P.'>WPZ</a> <font color='red'>-5.5%</font>, <a href='https://seekingalpha.com/symbol/MPLX' title='MPLX LP'>MPLX</a> <font color='red'>-3%</font>, <a href='https://seekingalpha.com/symbol/SEP' title='Spectra Energy Partners, LP'>SEP</a> <font color='red'>-6.1%</font>, <a href='https://seekingalpha.com/symbol/PAA' title='Plains All American Pipeline, L.P.'>PAA</a> <font color='red'>-4.7%</font>, <a href='https://seekingalpha.com/symbol/MMP' title='Magellan Midstream Partners, L.P.'>MMP</a> <font color='red'>-6.3%</font>, <a href='https://seekingalpha.com/symbol/CQP' title='Cheniere Energy Partners, LP'>CQP</a> <font color='red'>-2.7%</font>, <a href='https://seekingalpha.com/symbol/WGP' title='Western Gas Equity Partners, LP'>WGP</a> <font color='red'>-1.3%</font>, <a href='https://seekingalpha.com/symbol/WES' title='Western Gas Partners, L.P.'>WES</a> <font color='red'>-2.4%</font>, <a href='https://seekingalpha.com/symbol/APO' title='Apollo Global Management, LLC'>APO</a> <font color='red'>-1.4%</font>, <a href='https://seekingalpha.com/symbol/EQGP' title='EQT GP Holdings LP'>EQGP</a> <font color='red'>-3.8%</font>, <a href='https://seekingalpha.com/symbol/PSXP' title='Phillips 66 Partners LP'>PSXP</a> <font color='red'>-4.7%</font>, <a href='https://seekingalpha.com/symbol/ENBL' title='Enable Midstream Partners LP'>ENBL</a> <font color='red'>-4.2%</font>, <a href='https://seekingalpha.com/symbol/BEP' title='Brookfield Renewable Partners L.P.'>BEP</a> <font color='red'>-0.7%</font>.</li><li>ETFs: <a href='https://seekingalpha.com/symbol/XLE' title='Energy Select Sector SPDR ETF'>XLE</a>, <a href='https://seekingalpha.com/symbol/AMLP' title='ALPS Alerian MLP ETF'>AMLP</a>, <a href='https://seekingalpha.com/symbol/AMZA' title='InfraCap MLP ETF'>AMZA</a>, <a href='https://seekingalpha.com/symbol/KYN' title='Kayne Anderson MLP/Midstream Investment Company'>KYN</a>, <a href='https://seekingalpha.com/symbol/AMJ' title='JPMorgan Alerian MLP Index ETN'>AMJ</a>, <a href='https://seekingalpha.com/symbol/TYG' title='Tortoise Energy Infrastructure'>TYG</a>, <a href='https://seekingalpha.com/symbol/KYE' title='Kayne Anderson Energy Total Return Fund'>KYE</a>, <a href='https://seekingalpha.com/symbol/JMF' title='Nuveen Energy MLP Total Return Fund'>JMF</a>, <a href='https://seekingalpha.com/symbol/FMO' title='Fiduciary/Claymore MLP Opportunity Fund'>FMO</a>, <a href='https://seekingalpha.com/symbol/CEM' title='ClearBridge Energy MLP Fund'>CEM</a>, <a href='https://seekingalpha.com/symbol/CBA' title='ClearBridge American Energy MLP Fund Inc'>CBA</a>, <a href='https://seekingalpha.com/symbol/NML' title='Neuberger Berman MLP Income Fund Inc.'>NML</a>, <a href='https://seekingalpha.com/symbol/SRV' title='Cushing MLP & Infrastructure Total Return Fund'>SRV</a>, <a href='https://seekingalpha.com/symbol/MLPA' title='Global X MLP ETF'>MLPA</a>, <a href='https://seekingalpha.com/symbol/MLPI' title='UBS ETRACS Alerian MLP Infrastructure Index ETN'>MLPI</a>, <a href='https://seekingalpha.com/symbol/FEN' title='First Trust Energy Income&Growth Fund'>FEN</a>, <a href='https://seekingalpha.com/symbol/NTG' title='Tortoise MLP Fund'>NTG</a>, <a href='https://seekingalpha.com/symbol/GER' title='Goldman Sachs MLP and Energy Renaissance Fund'>GER</a>, <a href='https://seekingalpha.com/symbol/FEI' title='First Trust MLP&Energy Income Fund'>FEI</a>, <a href='https://seekingalpha.com/symbol/KMF' title='Kayne Anderson Midstream/Energy Fund'>KMF</a>, <a href='https://seekingalpha.com/symbol/MLPQ' title='ETRACS 2xMonthly Leveraged Alerian MLP Infrastructure Index ETN Series B'>MLPQ</a>, <a href='https://seekingalpha.com/symbol/CEN' title='Center Coast MLP & Infrastructure Fund'>CEN</a>, <a href='https://seekingalpha.com/symbol/EMLP' title='First Trust North American Energy Infrastructure ETF'>EMLP</a>, <a href='https://seekingalpha.com/symbol/MLPX' title='Global X MLP & Energy Infrastructure ETF'>MLPX</a>, <a href='https://seekingalpha.com/symbol/EMO' title='ClearBridge Energy MLP Opportunity Fund Inc.'>EMO</a>, <a href='https://seekingalpha.com/symbol/FPL' title='First Trust New Opportunities MLP & Energy Fund'>FPL</a>, <a href='https://seekingalpha.com/symbol/MIE' title='Cohen & Steers MLP Income and Energy Opportunity Fund, Inc.'>MIE</a>, <a href='https://seekingalpha.com/symbol/GMZ' title='GS MLP Income Opportunities Fund'>GMZ</a>, <a href='https://seekingalpha.com/symbol/DSE' title='Duff & Phelps Select Energy MLP Fund Inc.'>DSE</a>, <a href='https://seekingalpha.com/symbol/MLPG' title='UBS ETRACS Alerian Natural Gas MLP Index ETN'>MLPG</a>, <a href='https://seekingalpha.com/symbol/TTP' title='Tortoise Pipeline&Energy Fund'>TTP</a>, <a href='https://seekingalpha.com/symbol/SRF' title='Cushing Energy Income Fund'>SRF</a>, <a href='https://seekingalpha.com/symbol/CTR' title='ClearBridge Energy MLP Total Return Fund, Inc.'>CTR</a>, <a href='https://seekingalpha.com/symbol/MLPN' title='Credit Suisse Equal Weight MLP Index ETN due on 4/20/2020'>MLPN</a>, <a href='https://seekingalpha.com/symbol/SMM' title='Salient Midstream&MLP Fund'>SMM</a>, <a href='https://seekingalpha.com/symbol/JMLP' title='Nuveen All Cap Energy MLP Opportunities Fund'>JMLP</a>, <a href='https://seekingalpha.com/symbol/MLPS' title='UBS ETRACS 1x Monthly Short Alerian MLP Infrastructure Total Return ETN'>MLPS</a>, <a href='https://seekingalpha.com/symbol/AMU' title='UBS ETRACS Alerian MLP Index ETN'>AMU</a>, <a href='https://seekingalpha.com/symbol/ENFR' title='ALPS Alerian Energy Infrastructure ETF'>ENFR</a>, <a href='https://seekingalpha.com/symbol/ATMP' title='Barclays ETN+ Select MLP ETN'>ATMP</a>, <a href='https://seekingalpha.com/symbol/AMJL' title='Credit Suisse X-Links Monthly Pay 2xLeveraged Alerian MLP Index ETN'>AMJL</a>, <a href='https://seekingalpha.com/symbol/MLPZ' title='ETRACS 2xMonthly Leveraged S&P MLP Index ETN Series B'>MLPZ</a>, <a href='https://seekingalpha.com/symbol/IMLP' title='iPath S&P MLP ETN'>IMLP</a>, <a href='https://seekingalpha.com/symbol/ILPRX' title='Invesco MLP Fund Retirement'>ILPRX</a>, <a href='https://seekingalpha.com/symbol/AMUB' title='ETRACS Alerian MLP Index ETN Series B'>AMUB</a>, <a href='https://seekingalpha.com/symbol/MLPB' title='ETRACS Alerian MLP Infrastructure Index ETN Series B'>MLPB</a>, <a href='https://seekingalpha.com/symbol/MLPO' title='Credit Suisse S&P MLP Index ETN'>MLPO</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3339594\" data-linked=\"MLPs suffer sharp losses as FERC nixes income tax allowance cost recovery\" data-tweet=\"$EEP $EEP $WMB - MLPs suffer sharp losses as FERC nixes income tax allowance cost recovery https://seekingalpha.com/news/3339594-mlps-suffer-sharp-losses-ferc-nixes-income-tax-allowance-cost-recovery?source=tweet\" data-url=\"https://seekingalpha.com/news/3339594-mlps-suffer-sharp-losses-ferc-nixes-income-tax-allowance-cost-recovery\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:56 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>472&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3339592\" data-ts=\"1521132612\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DXR\" target=\"_blank\">DXR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3339592-midday-gainers-losers-3-15-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers / Losers (3/15/2018)</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/DXR' title='Daxor Corp'>DXR</a> <font color='green'>+156%</font>. <a href='https://seekingalpha.com/symbol/KBSF' title='KBS Fashion Group Limited'>KBSF</a> <font color='green'>+68%</font>. RXII <font color='green'>+40%</font>. <a href='https://seekingalpha.com/symbol/ISNS' title='Image Sensing Systems, Inc.'>ISNS</a> <font color='green'>+38%</font>. <a href='https://seekingalpha.com/symbol/AKCA' title='Akcea Therapeutics'>AKCA</a> <font color='green'>+27%</font>. <a href='https://seekingalpha.com/symbol/ADAP' title='Adaptimmune Therapeutics plc'>ADAP</a> <font color='green'>+22%</font>. <a href='https://seekingalpha.com/symbol/CWAY' title='Coastway Bancorp, Inc.'>CWAY</a> <font color='green'>+21%</font>. <a href='https://seekingalpha.com/symbol/CVTI' title='Covenant Transportation Group, Inc.'>CVTI</a> <font color='green'>+18%</font>. <a href='https://seekingalpha.com/symbol/OSN' title='Ossen Innovation Co., Ltd.'>OSN</a> <font color='green'>+17%</font>. <a href='https://seekingalpha.com/symbol/NDLS' title='Noodles & Company'>NDLS</a> <font color='green'>+17%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/JILL' title='J. Jill Group, Inc.'>JILL</a> <font color='red'>-35%</font>. <a href='https://seekingalpha.com/symbol/YTEN' title='Yield10 Bioscience, Inc.'>YTEN</a> <font color='red'>-27%</font>. <a href='https://seekingalpha.com/symbol/SPEX' title='Spherix Incorporated'>SPEX</a> <font color='red'>-24%</font>. <a href='https://seekingalpha.com/symbol/ASUR' title='Asure Software, Inc.'>ASUR</a> <font color='red'>-21%</font>. <a href='https://seekingalpha.com/symbol/ABDC' title='Alcentra Capital Corporation'>ABDC</a> <font color='red'>-19%</font>. <a href='https://seekingalpha.com/symbol/EVC' title='Entravision Communications Corporation'>EVC</a> <font color='red'>-18%</font>. <a href='https://seekingalpha.com/symbol/SPWH' title='Sportsman&#39;s Warehouse Holdings, Inc.'>SPWH</a> <font color='red'>-18%</font>. <a href='https://seekingalpha.com/symbol/SFS' title='Smart & Final Stores'>SFS</a> <font color='red'>-17%</font>. <a href='https://seekingalpha.com/symbol/SEED' title='Origin Agritech Limited'>SEED</a> <font color='red'>-17%</font>. <a href='https://seekingalpha.com/symbol/EEP' title='Enbridge Energy Partners L.P.'>EEP</a> <font color='red'>-16%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3339592\" data-linked=\"Midday Gainers / Losers (3/15/2018)\" data-tweet=\"$DXR $DXR $KBSF - Midday Gainers / Losers (3/15/2018) https://seekingalpha.com/news/3339592-midday-gainers-losers-3-15-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3339592-midday-gainers-losers-3-15-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:50 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3339591\" data-ts=\"1521132049\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AVGO\" target=\"_blank\">AVGO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3339591-broadcom-gains-analysts-come-back-in-top-pick-ratings\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Broadcom gains as analysts come back in with top-pick ratings</a></h4><ul>   <li>With a <a href=\"https://seekingalpha.com/news/3338543-trump-issues-order-block-broadcom-takeover-qualcomm\" target=\"_blank\">dramatic end</a> to the largest-ever tech deal, Broadcom (<a href=\"http://seekingalpha.com/symbol/AVGO\" target=\"_blank\">AVGO</a> <font color='green'>+2.7%</font>) is back on the upswing today after analysts resume Buy ratings in a re-evaluation of prospects for the chipmaker.</li>    <li>BofA Merrill Lynch resumed coverage as <a href=\"https://www.benzinga.com/analyst-ratings/analyst-color/18/03/11366969/broadcom-still-a-top-pick-among-analysts-despite-blocke\" target=\"_blank\">one of its top picks</a>, pointing to factors including a diversified product portfolio, a sector-leading dividend yield and industry-topping operating margin of 48.9%, sustainable long-term organic sales, potential for 40% FCF and a still-discounted trade price. The firm has a $340 price target, implying 27% upside.</li>    <li>Meanwhile, RBC's Amit Daryanani reiterates a top-pick stance on Broadcom, and says that the company's next acquisition may look more like its deal for Brocade Communications -- not a \"classic\" chip company but one fitting parameters like a gross margin over 50% and market cap of $10B-$120B, like Citrix (<a href=\"http://seekingalpha.com/symbol/CTXS\" target=\"_blank\">CTXS</a> <font color='green'>+0.5%</font>), NetApp (<a href=\"http://seekingalpha.com/symbol/NTAP\" target=\"_blank\">NTAP</a> <font color='red'>-0.7%</font>), Juniper Networks (<a href=\"http://seekingalpha.com/symbol/JNPR\" target=\"_blank\">JNPR</a> <font color='green'>+0.3%</font>) or CA (<a href=\"http://seekingalpha.com/symbol/CA\" target=\"_blank\">CA</a> <font color='red'>-0.2%</font>). (h/t Bloomberg)</li>    <li>Deutsche Bank resumed coverage at Buy with a $325 price target; now the company can get back to a strategy of allocating cash between dividends and M&amp;A, Ross Seymore says, expecting a mix shift toward dividends.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3339591\" data-linked=\"Broadcom gains as analysts come back in with top-pick ratings\" data-tweet=\"$AVGO $AVGO $CTXS - Broadcom gains as analysts come back in with top-pick ratings https://seekingalpha.com/news/3339591-broadcom-gains-analysts-come-back-in-top-pick-ratings?source=tweet\" data-url=\"https://seekingalpha.com/news/3339591-broadcom-gains-analysts-come-back-in-top-pick-ratings\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:40 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3339566\" data-ts=\"1521131660\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SQ\" target=\"_blank\">SQ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3339566-bitcoin-acceptance-strong-catalyst-for-square-nomura-instinet\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bitcoin acceptance a strong catalyst for Square - Nomura Instinet</a></h4><ul><li><a href=\"https://www.cnbc.com/2018/03/14/nomura-insitnet-square-like-amazon-in-its-early-days.html?__source=twitter%7Cmain\" target=\"_blank\">The company's push into the crypto world</a> will lead the company higher as merchants' willingness to accept Bitcoin is on the rise. More than 60% of merchants surveyed by the company responded \"Yes\" to accept Bitcoin as a form of payment.</li><li>Analyst Dan Dolev wrote, \"Like Amazon in its early days, we believe that little of the future revenue streams are currently visible,\" he adds, \"Undoubtedly, the success of the Cash App is a significant achievement, currently an individual can set up the app in minutes and send peer-to-peer payments, store money, receive their paycheck and buy and sell bitcoin.\"</li><li>Nomura Instinet reiterated its Buy on Square (<a href='https://seekingalpha.com/symbol/SQ' title='Square, Inc.'>SQ</a> <font color='red'>-0.1%</font>)&nbsp;with a $64 price target offering 17% upside.</li></ul><div class=\"tiny-share-widget\" data-id=\"3339566\" data-linked=\"Bitcoin acceptance a strong catalyst for Square - Nomura Instinet\" data-tweet=\"$SQ - Bitcoin acceptance a strong catalyst for Square - Nomura Instinet https://seekingalpha.com/news/3339566-bitcoin-acceptance-strong-catalyst-for-square-nomura-instinet?source=tweet\" data-url=\"https://seekingalpha.com/news/3339566-bitcoin-acceptance-strong-catalyst-for-square-nomura-instinet\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:34 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>28&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3339581\" data-ts=\"1521131332\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GS\" target=\"_blank\">GS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3339581-goldman-to-launch-startup-incubator-firm-business-insider\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Goldman to launch a startup incubator at the firm - Business Insider</a></h4><ul><li>The firm wants to launch a start-up incubator open for all employees as it tries to reign in on Wall Street's talent drain.</li><li><a href=\"http://www.businessinsider.com/goldman-sachs-is-launching-an-incubator-to-create-a-startup-engine-within-the-wall-street-giant-2018-3\" target=\"_blank\">The internal memo seen by Business Insider said</a>, \"By applying to GS Accelerate, you will have an opportunity to submit ideas that can deliver best-in-class solutions for our clients, take the firm into new business areas, manage risk, and tackle inefficiencies in our operations.\"</li><li>The idea is to have employees pitch their ideas to the firm's senior management where approvals will take place. The mechanics will be tricky since a fixed income trader with an idea in the retail banking space will have face a good deal of scrutiny.</li><li>Goldman Sachs <a href='https://seekingalpha.com/symbol/GS' title='Goldman Sachs Group Inc.'>GS</a> shares are&nbsp;<font color='green'>up&nbsp;+1.5%&nbsp;</font>today.</li></ul><div class=\"tiny-share-widget\" data-id=\"3339581\" data-linked=\"Goldman to launch a startup incubator at the firm - Business Insider\" data-tweet=\"$GS - Goldman to launch a startup incubator at the firm - Business Insider https://seekingalpha.com/news/3339581-goldman-to-launch-startup-incubator-firm-business-insider?source=tweet\" data-url=\"https://seekingalpha.com/news/3339581-goldman-to-launch-startup-incubator-firm-business-insider\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:28 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3339582\" data-ts=\"1521130984\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MSFT\" target=\"_blank\">MSFT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3339582-microsoft-launches-cloud-gaming-division-offers-250k-cpu-bug-bounty\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Microsoft launches cloud gaming division, offers $250K CPU bug bounty</a></h4><ul><li>        Microsoft (NASDAQ:<a href='https://seekingalpha.com/symbol/MSFT' title='Microsoft Corporation'>MSFT</a>) launches a new <a href=\"https://www.cnbc.com/2018/03/15/microsofts-cloud-business-just-unveiled-a-new-video-game-division.html\" target=\"_blank\">gaming cloud division</a>.</li><li>               Kareem Choudhry, who has worked on Outlook an Xbox engineering, will head the new division and report to recently appointed gaming head Phil Spencer.&nbsp;</li><li>               Ubisoft already use Microsoft&rsquo;s Azure cloud service for its Rainbow Six: Siege title across PC, Xbox, and PS4. Microsoft hopes more developers in the future will move to the cloud, which enables easier multiplayer experiences across devices.&nbsp;</li><li>                  Microsoft has acquired a few companies in recent years that hinted at a shift towards cloud gaming. The most recent acquisition was PlayFab earlier this year.    </li><li>               In other Microsoft news, the company is offering up a <a href=\"https://www.theverge.com/2018/3/15/17124362/microsoft-spectre-bug-bounty-speculative-execution\" target=\"_blank\">$250K bug bounty</a> for &ldquo;speculative execution&rdquo; of recently disclosed CPU vulnerabilities that resemble the Meltdown and Spectre CPU flaws that struck Intel.&nbsp;</li><li>               Microsoft shares are&nbsp;<font color='green'>up 0.4%</font>&nbsp;to $94.24.&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3326138-microsoft-acquires-backend-game-platform-provider-azure\" target=\"_blank\">Microsoft acquires backend game platform provider for Azure</a> (Jan. 29)</li></ul><div class=\"tiny-share-widget\" data-id=\"3339582\" data-linked=\"Microsoft launches cloud gaming division, offers $250K CPU bug bounty\" data-tweet=\"$MSFT - Microsoft launches cloud gaming division, offers $250K CPU bug bounty https://seekingalpha.com/news/3339582-microsoft-launches-cloud-gaming-division-offers-250k-cpu-bug-bounty?source=tweet\" data-url=\"https://seekingalpha.com/news/3339582-microsoft-launches-cloud-gaming-division-offers-250k-cpu-bug-bounty\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:23 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3339578\" data-ts=\"1521129787\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KBSF\" target=\"_blank\">KBSF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3339578-consumer-top-gainers-losers-of-12-00-pm-3-15-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Consumer - Top Gainers / Losers as of 12:00 pm (3/15/2018)</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/KBSF' title='KBS Fashion Group Limited'>KBSF</a> <font color='green'>+17%</font>. <a href='https://seekingalpha.com/symbol/DFBG-OLD' title='Differential Brands Group Inc.'>DFBG-OLD</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/ADOM' title='ADOMANI, Inc.'>ADOM</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/ZX' title='China Zenix Auto International'>ZX</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/VRA' title='Vera Bradley'>VRA</a> <font color='green'>+7%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/SEED' title='Origin Agritech Limited'>SEED</a> <font color='red'>-15%</font>. <a href='https://seekingalpha.com/symbol/SPWH' title='Sportsman&#39;s Warehouse Holdings, Inc.'>SPWH</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/VUZI' title='Vuzix Corp'>VUZI</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/LCUT' title='Lifetime Brands, Inc.'>LCUT</a> <font color='red'>-9%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3339578\" data-linked=\"Consumer - Top Gainers / Losers as of 12:00 pm (3/15/2018)\" data-tweet=\"$KBSF $KBSF $DFBG-OLD - Consumer - Top Gainers / Losers as of 12:00 pm (3/15/2018) https://seekingalpha.com/news/3339578-consumer-top-gainers-losers-of-12-00-pm-3-15-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3339578-consumer-top-gainers-losers-of-12-00-pm-3-15-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:03 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3339577\" data-ts=\"1521129776\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SVA\" target=\"_blank\">SVA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3339577-sinovac-confirms-reelection-of-board-members\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sinovac confirms reelection of board members</a></h4><ul><li>In response to alleged misstatements from dissident shareholders and others, Sinovac Biotech Ltd. (<a href='https://seekingalpha.com/symbol/SVA' title='Sinovac Biotech, Ltd.'>SVA</a> <font color='green'>+1.7%</font>) <a href=\"https://seekingalpha.com/pr/17102816-sinovac-sets-record-straight-regarding-false-statements-unauthorized-third-parties\" target=\"_blank\">announces </a>that all five incumbent board members were properly reelected at the recent Annual Meeting.</li><li>Apparently, certain parties publicly claimed control of the company.</li></ul><div class=\"tiny-share-widget\" data-id=\"3339577\" data-linked=\"Sinovac confirms reelection of board members\" data-tweet=\"$SVA - Sinovac confirms reelection of board members https://seekingalpha.com/news/3339577-sinovac-confirms-reelection-of-board-members?source=tweet\" data-url=\"https://seekingalpha.com/news/3339577-sinovac-confirms-reelection-of-board-members\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:02 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3339576\" data-ts=\"1521129554\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MON\" target=\"_blank\">MON</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3339576-monsantominus-5-bayer-tie-up-reportedly-faces-antitrust-hurdles\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Monsanto -5% as Bayer tie-up reportedly faces more antitrust hurdles</a></h4><ul>     <li>Monsanto (<a href='https://seekingalpha.com/symbol/MON' title='Monsanto Company'>MON</a> <font color='red'>-4.6%</font>) shares drop sharply following a Bloomberg report that its pending takeover by Bayer (<a href='https://seekingalpha.com/symbol/BAYRY' title='Bayer A.G. ADR'>OTCPK:BAYRY</a> <font color='green'>+0.1%</font>) <a href=\"https://www.bloomberg.com/news/articles/2018-03-15/bayer-is-said-to-face-u-s-hurdles-for-monsanto-antitrust-nod\" target=\"_blank\">faces additional hurdles for U.S. antitrust approval</a>.</li>     <li>The U.S. Justice Department&rsquo;s antitrust division thinks Bayer&rsquo;s proposal to sell businesses does not go far enough, and it wants the German company to divest more assets to resolve its concerns, according to the report.</li>     <li>Negotiations between the two sides reportedly are continuing and a final decision by the government likely is months away.</li></ul><div class=\"tiny-share-widget\" data-id=\"3339576\" data-linked=\"Monsanto -5% as Bayer tie-up reportedly faces more antitrust hurdles\" data-tweet=\"$MON $MON $BAYRY - Monsanto -5% as Bayer tie-up reportedly faces more antitrust hurdles https://seekingalpha.com/news/3339576-monsantominus-5-bayer-tie-up-reportedly-faces-antitrust-hurdles?source=tweet\" data-url=\"https://seekingalpha.com/news/3339576-monsantominus-5-bayer-tie-up-reportedly-faces-antitrust-hurdles\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:59 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3339573\" data-ts=\"1521129410\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MTP\" target=\"_blank\">MTP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3339573-new-chief-midtech\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">New chief at Midtech</a></h4><ul><li>Midatech Pharma (<a href='https://seekingalpha.com/symbol/MTP' title='Midatech Pharma PLC'>MTP</a> <font color='green'>+8.6%</font>) <a href=\"https://seekingalpha.com/pr/17103068-midatech-announces-changes-senior-management-team\" target=\"_blank\">announces </a>that CEO Dr. Jim Phillips will step down at the end of May. COO and Head of R&amp;D Craig Cook, M.D. will succeed him.</li><li>SVP of Translational Medicine Dr. Steve Damment will succeed Dr. Cook as R&amp;D chief.</li></ul><div class=\"tiny-share-widget\" data-id=\"3339573\" data-linked=\"New chief at Midtech\" data-tweet=\"$MTP - New chief at Midtech https://seekingalpha.com/news/3339573-new-chief-midtech?source=tweet\" data-url=\"https://seekingalpha.com/news/3339573-new-chief-midtech\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:56 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3339572\" data-ts=\"1521129077\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IIVI\" target=\"_blank\">IIVI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3339572-ii-vi-initiated-23-upside\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">II-VI initiated at 23% upside</a></h4><ul><li>        DA Davidson<a href=\"https://www.streetinsider.com/Analyst+Comments/DA+Davidson+Starts+II-VI%2C+Inc.+%28IIVI%29+at+Buy/13944886.html\" target=\"_blank\"> starts</a> II-VI (NASDAQ:<a href='https://seekingalpha.com/symbol/IIVI' title='II-VI Incorporated'>IIVI</a>) at Buy with a $55 price target, a 23% upside to yesterday&rsquo;s close</li><li>        Analyst Thomas Diffely cites the company&rsquo;s &ldquo;many irons&rdquo; in the fire.</li><li>               II-VI shares are&nbsp;<font color='green'>up 2.2%</font>&nbsp;to $45.78. &nbsp;&nbsp; &nbsp;&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3339572\" data-linked=\"II-VI initiated at 23% upside\" data-tweet=\"$IIVI - II-VI initiated at 23% upside https://seekingalpha.com/news/3339572-ii-vi-initiated-23-upside?source=tweet\" data-url=\"https://seekingalpha.com/news/3339572-ii-vi-initiated-23-upside\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:51 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3339569\" data-ts=\"1521128542\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JILL\" target=\"_blank\">JILL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3339569-bruising-day-for-j-jill\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bruising day for J. Jill</a></h4><ul> <li>J. Jill (NYSE:<a href='https://seekingalpha.com/symbol/JILL' title='J. Jill Group, Inc.'>JILL</a>) is&nbsp;<font color='red'>down 35.5%</font>&nbsp;after the company's earnings report and CEO retirement rattle investors.</li> <li>Guidance from the retailer was also on the alarming side. J. Jill expects comparable sales to fall at a mid single-digit clip in Q1 due to \"challenges\" in the direct business.</li> <li>Shares of J. Jill traded as low as $4.74. The IPO was priced just over a year ago at $13 per share.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3339380-j-jill-announces-ceo-transition\" target=\"_blank\">J.Jill announces CEO transition</a> (March 15)</li> <li>Previously: <a href=\"https://seekingalpha.com/news/3339414-j-jill-beats-q4-estimates\" target=\"_blank\">J.Jill beats Q4 estimates</a> (March 15)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3339569\" data-linked=\"Bruising day for J. Jill\" data-tweet=\"$JILL - Bruising day for J. Jill https://seekingalpha.com/news/3339569-bruising-day-for-j-jill?source=tweet\" data-url=\"https://seekingalpha.com/news/3339569-bruising-day-for-j-jill\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:42 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3339567\" data-ts=\"1521128085\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/XNET\" target=\"_blank\">XNET</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3339567-xunlei-slips-despite-cloud-juiced-revenue-doubling\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Xunlei slips despite cloud-juiced revenue doubling</a></h4><ul>   <li>Xunlei Limited (NASDAQ:<a href='https://seekingalpha.com/symbol/XNET' title='Xunlei Limited'>XNET</a>) is <font color='red'>6.7% lower</font> after its delayed <a href=\"https://seekingalpha.com/news/3339343-xunlei-reports-q4-results\" target=\"_blank\">Q4 earnings</a> report showed a swing to a gain amid revenues that doubled thanks to cloud computing.</li>    <li>Net income from continuing operations came to $3M, vs. a year-ago loss of $8.5M.</li>    <li>\"Our fourth quarter revenues met our upwardly revised guidance range as our cloud computing business expanded at a fast pace during the fourth quarter of 2017,\" said CEO Lei Chen. \"Our priority for 2018 is to gain market shares and continue to improve the bottom line.&rdquo;</li>    <li>Revenue by segment: Subscription, $22.7M (up 4.5%); Online advertising including mobile, $7.8M; Internet value-added services, $51.9M (up 431.6%).</li>    <li>Cash, equivalents and short-term investments came to $372.4M, down from the prior year's $381.5M.</li>    <li>For Q1, it's guiding to revenues of $81M-$85M (a 129% Y/Y gain at the midpoint).</li>    <li><a href=\"https://seekingalpha.com/pr/17102684-xunlei-announces-unaudited-financial-results-fourth-quarter-fiscal-year-ended-december-31\" target=\"_blank\">Press release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3339567\" data-linked=\"Xunlei slips despite cloud-juiced revenue doubling\" data-tweet=\"$XNET - Xunlei slips despite cloud-juiced revenue doubling https://seekingalpha.com/news/3339567-xunlei-slips-despite-cloud-juiced-revenue-doubling?source=tweet\" data-url=\"https://seekingalpha.com/news/3339567-xunlei-slips-despite-cloud-juiced-revenue-doubling\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:34 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3339564\" data-ts=\"1521127712\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PCTY\" target=\"_blank\">PCTY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3339564-needham-raises-paylocity-target-to-18-upside\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Needham raises its Paylocity target to 18% upside</a></h4><ul><li>        Needham maintains a Buy rating and raises its Paylocity (NASDAQ:<a href='https://seekingalpha.com/symbol/PCTY' title='Paylocity Holding Corp'>PCTY</a>) price target by $5 to $65, an 18% upside to yesterday&rsquo;s close.</li><li>               Firm came away from investor meetings with CEO Steve Beauchamp feeling positive about the health of end-market demand and believes subscription revenue can grow 20%.&nbsp;</li><li>               Needham believes near-term model leverage from G&amp;A or COGS, rather than S&amp;M, will drive overall EBITDA margins to surpass the prior 20% to 25% goals in the near future.&nbsp;</li><li>               Source: Briefing.com.&nbsp;</li><li>               Paylocity shares are<font color='red'> down 0.5%</font>&nbsp;to $54.97.&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3339564\" data-linked=\"Needham raises its Paylocity target to 18% upside\" data-tweet=\"$PCTY - Needham raises its Paylocity target to 18% upside https://seekingalpha.com/news/3339564-needham-raises-paylocity-target-to-18-upside?source=tweet\" data-url=\"https://seekingalpha.com/news/3339564-needham-raises-paylocity-target-to-18-upside\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:28 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3339563\" data-ts=\"1521127473\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ACIU\" target=\"_blank\">ACIU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3339563-ac-immune-to-launch-first-in-human-study-of-pet-tracer-for-parkinsons-in-h2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AC Immune to launch first in-human study of PET tracer for Parkinson&#39;s in H2</a></h4><ul><li>AC Immune (<a href='https://seekingalpha.com/symbol/ACIU' title='AC Immune SA'>ACIU</a> <font color='red'>-0.4%</font>) <a href=\"https://seekingalpha.com/pr/17102773-ac-immune-prepares-first-human-study-promising-positron-emission-tomography-pet-tracer\" target=\"_blank\">announces </a>that it plans to initiate a first in-human study of its investigational PET imaging agent for Parkinson's disease &#40;PD&#41;. The company says the agent is highly selective for alpha-synuclein aggregates, an established drug target for the disorder. The tracer will enable PD drug developers to monitor the efficacy of PD therapies.</li><li>The company has been collaborating with Biogen (<a href='https://seekingalpha.com/symbol/BIIB' title='Biogen Inc.'>BIIB</a> <font color='green'>+0.3%</font>) on the program for almost two years on a non-exclusive basis.</li><li>Shares were up over&nbsp;<font color='green'>5%</font>&nbsp;before retracing.</li></ul><div class=\"tiny-share-widget\" data-id=\"3339563\" data-linked=\"AC Immune to launch first in-human study of PET tracer for Parkinson&#39;s in H2\" data-tweet=\"$ACIU $ACIU $BIIB - AC Immune to launch first in-human study of PET tracer for Parkinson&#39;s in H2 https://seekingalpha.com/news/3339563-ac-immune-to-launch-first-in-human-study-of-pet-tracer-for-parkinsons-in-h2?source=tweet\" data-url=\"https://seekingalpha.com/news/3339563-ac-immune-to-launch-first-in-human-study-of-pet-tracer-for-parkinsons-in-h2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:24 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3339561\" data-ts=\"1521127184\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PBR\" target=\"_blank\">PBR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3339561-petrobras-posts-loss-on-settlement-costs\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Petrobras posts loss on settlement costs</a></h4><ul>     <li>Petrobras (<a href='https://seekingalpha.com/symbol/PBR' title='Petrobras - Petroleo Brasileiro S.A.'>PBR</a> <font color='red'>-2%</font>)&nbsp;is lower after <a href=\"http://files.investidorpetrobras.com.br/conteudo/IMPRENSA-4T17-Ingles-15-03-2018.pdf\" target=\"_blank\">reporting a Q4 net loss</a> of 5.48B reais ($1.68B) and a full-year net loss of 466M reais, weighed by a $3.4B settlement to end a class action lawsuit in the U.S.</li>     <li>PBR says it would have earned a net profit of 7.1B reais in 2017 without a series of extraordinary payments, including the settlement ending a class-action lawsuit by U.S. investors who had sought to recoup corruption-related losses.</li>     <li>General and administrative expenses fell 19% in 2017 to 9.3B reais after the company cut staff through employee buyouts and reduced expenses.</li>     <li>PBR says it cut its net debt to $84.9B at the end of 2017, the lowest level since 2012, lengthened the average life of the debt to 8.6 years from 7.5 years and cut the average interest rate to 5.9% from 6.2%.</li>     <li>The results show PBR \"is <a href=\"https://www.wsj.com/articles/brazils-petrobras-posts-loss-following-settlement-charges-1521117187\" target=\"_blank\">turning the page</a> on problems related to Car Wash,\" according to Shin Lai, an investment strategist at S&atilde;o Paulo-based Upside Investor. &ldquo;The change is happening and it&rsquo;s consistent.&rdquo;</li> </ul><div class=\"tiny-share-widget\" data-id=\"3339561\" data-linked=\"Petrobras posts loss on settlement costs\" data-tweet=\"$PBR - Petrobras posts loss on settlement costs https://seekingalpha.com/news/3339561-petrobras-posts-loss-on-settlement-costs?source=tweet\" data-url=\"https://seekingalpha.com/news/3339561-petrobras-posts-loss-on-settlement-costs\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:19 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3339559\" data-ts=\"1521127025\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FEYE\" target=\"_blank\">FEYE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3339559-fireeyeplus-4_3-after-information-discusses-acquisition-potential\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FireEye +4.3% after The Information discusses acquisition potential</a></h4><ul><li>        FireEye (NASDAQ:<a href='https://seekingalpha.com/symbol/FEYE' title='FireEye, Inc.'>FEYE</a>) shares gain 4.3% after a <a href=\"https://www.theinformation.com/articles/tech-industry-watches-fireeyes-turnaround-effort?jwt=eyJhbGciOiJIUzI1NiJ9.eyJzdWIiOiJjcmFwaXNhcmRhQGJyaWVmaW5nLmNvbSIsImV4cCI6MTU1MjY4MjI5NCwibiI6Ikd1ZXN0Iiwic2NvcGUiOlsic2hhcmUiXX0.sAC9sB_8aE9fyvMw7EStvyNkFTzWm9QK8uoFB8_p1_8&amp;unlock=b5d50019906cdc9e\" target=\"_blank\">The Information</a> article says Cisco (<a href='https://seekingalpha.com/symbol/CSCO' title='Cisco Systems, Inc.'>CSCO</a> <font color='green'>+0.6%</font>) and Symantec (<a href='https://seekingalpha.com/symbol/SYMC' title='Symantec Corporation'>SYMC</a> <font color='green'>+0.3%</font>) have looked into buying the company.</li><li>           Potential acquirers could want the company for the expertise of CEO Kevin Mandia, who started in the U.S. Army before founding Mandiant, which earned press for tying largescale cybersecurity attacks on U.S. companies to Chinese attackers. </li><li> Mandiant was sold to FireEye in 2013 for about $900M. Mandia became FireEye&rsquo;s CEO in mid-2016. </li><li> Mandia is leading a turnaround effort to stop expanding losses due to slow sales and high spending. He cut the staff by 10% in his first year, reorganized the sales department, and launched a lower cost cloud software product as an alternative to the higher-priced hardware box. But FireEye is still mid-stride in the turnaround. </li><li> Piper Jaffray analyst Andrew Nowinski on Mandia&rsquo;s efforts: &ldquo;Their stock was almost uninvestable. It was hard to see a path to profitability in 2016. Over the past 12 months, he&rsquo;s really managed to get the business on track.&rdquo; </li><li> Key Mandia quote: &ldquo;If anyone bought us, I&rsquo;m still along for the ride and we have to operationally manage what we&rsquo;ve got.&rdquo;&nbsp; </li></ul><div class=\"tiny-share-widget\" data-id=\"3339559\" data-linked=\"FireEye +4.3% after The Information discusses acquisition potential\" data-tweet=\"$FEYE $FEYE $CSCO - FireEye +4.3% after The Information discusses acquisition potential https://seekingalpha.com/news/3339559-fireeyeplus-4_3-after-information-discusses-acquisition-potential?source=tweet\" data-url=\"https://seekingalpha.com/news/3339559-fireeyeplus-4_3-after-information-discusses-acquisition-potential\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:17 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>43&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3339530\" data-ts=\"1521126374\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DXR\" target=\"_blank\">DXR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3339530-healthcare-top-5-gainers-losers-of-11-05-3-15-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare - Top 5 Gainers / Losers as of 11:05 am (3/15/2018)</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/DXR' title='Daxor Corp'>DXR</a> <font color='green'>+77%</font>. <a href='https://seekingalpha.com/symbol/AKCA' title='Akcea Therapeutics'>AKCA</a> <font color='green'>+39%</font>. <a href='https://seekingalpha.com/symbol/ADAP' title='Adaptimmune Therapeutics plc'>ADAP</a> <font color='green'>+37%</font>. <a href='https://seekingalpha.com/symbol/AEMD' title='Aethlon Medical, Inc.'>AEMD</a> <font color='green'>+18%</font>. RXII <font color='green'>+15%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/SELB' title='Selecta Biosciences'>SELB</a> <font color='red'>-15%</font>. <a href='https://seekingalpha.com/symbol/IVTY' title='Invuity'>IVTY</a> <font color='red'>-15%</font>. <a href='https://seekingalpha.com/symbol/CPRX' title='Catalyst Pharmaceuticals, Inc.'>CPRX</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/CVRS' title='Corindus Vascular Robotics, Inc.'>CVRS</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/ARNA' title='Arena Pharmaceuticals, Inc.'>ARNA</a> <font color='red'>-10%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3339530\" data-linked=\"Healthcare - Top 5 Gainers / Losers as of 11:05 am (3/15/2018)\" data-tweet=\"$DXR $DXR $AKCA - Healthcare - Top 5 Gainers / Losers as of 11:05 am (3/15/2018) https://seekingalpha.com/news/3339530-healthcare-top-5-gainers-losers-of-11-05-3-15-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3339530-healthcare-top-5-gainers-losers-of-11-05-3-15-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:06 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3339551\" data-ts=\"1521126080\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VRAY\" target=\"_blank\">VRAY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3339551-viewrays-next-gen-mridian-system-okd-in-japan-shares-up-1\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ViewRay&#39;s next-gen MRIdian system OK&#39;d in Japan; shares up 1%</a></h4><ul><li>The Japanese Ministry of Health, Labor and Welfare has <a href=\"https://seekingalpha.com/pr/17103134-viewrays-mridian-mr-image-guided-radiotherapy-linac-receives-japanese-regulatory-approval\" target=\"_blank\">approved </a>ViewRay's (<a href='https://seekingalpha.com/symbol/VRAY' title='ViewRay'>VRAY</a> <font color='green'>+1.1%</font>) next-generation MRIdian Linac, an MRI-guided radiation system.</li><li>MRIdian cobalt was approved there in August 2016.</li></ul><div class=\"tiny-share-widget\" data-id=\"3339551\" data-linked=\"ViewRay&#39;s next-gen MRIdian system OK&#39;d in Japan; shares up 1%\" data-tweet=\"$VRAY - ViewRay&#39;s next-gen MRIdian system OK&#39;d in Japan; shares up 1% https://seekingalpha.com/news/3339551-viewrays-next-gen-mridian-system-okd-in-japan-shares-up-1?source=tweet\" data-url=\"https://seekingalpha.com/news/3339551-viewrays-next-gen-mridian-system-okd-in-japan-shares-up-1\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:01 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3339549\" data-ts=\"1521125486\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DDD\" target=\"_blank\">DDD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3339549-stifel-raises-3d-systems-target-after-earnings\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Stifel raises its 3D Systems target after earnings</a></h4><ul><li>           Stifel maintains a Hold rating but raises its 3D Systems (NYSE:<a href='https://seekingalpha.com/symbol/DDD' title='3D Systems Corp.'>DDD</a>) price target by a dollar to $12 (15 cents below yesterday&rsquo;s closing price) after the earnings report. </li><li>           Firm found the revenue trends impressive but watches from the sidelines for an extended period of revenue growth and new product launch details.  </li><li> Source: Briefing.com. </li><li> 3D Systems shares are&nbsp;<font color='green'>up 8.2%</font>&nbsp;to $13.14 with a 52-week range of $7.92 to $23.70.&nbsp; </li><li>Previously: <a href=\"https://seekingalpha.com/news/3339261-3d-systems-plus-11_1-percent-delayed-q4-beats\" target=\"_blank\">3D Systems +11.1% on delayed Q4 beats</a> (March 14)</li></ul><div class=\"tiny-share-widget\" data-id=\"3339549\" data-linked=\"Stifel raises its 3D Systems target after earnings\" data-tweet=\"$DDD - Stifel raises its 3D Systems target after earnings https://seekingalpha.com/news/3339549-stifel-raises-3d-systems-target-after-earnings?source=tweet\" data-url=\"https://seekingalpha.com/news/3339549-stifel-raises-3d-systems-target-after-earnings\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:51 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3339547\" data-ts=\"1521125263\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IONS\" target=\"_blank\">IONS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3339547-akcea-to-commercialize-ionis-pharmas-inotersen-shares-up-28\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Akcea to commercialize Ionis Pharma&#39;s inotersen; shares up 28%</a></h4><ul><li>Ionis Pharmaceuticals (<a href='https://seekingalpha.com/symbol/IONS' title='Ionis Pharmaceuticals, Inc.'>IONS</a> <font color='red'>-4.2%</font>) affiliate and majority-owned Akcea Therapeutics (<a href='https://seekingalpha.com/symbol/AKCA' title='Akcea Therapeutics'>AKCA</a> <font color='green'>+28.1%</font>) is up on 40% higher volume on the heels of its <a href=\"https://seekingalpha.com/pr/17102842-ionis-akcea-partner-commercialize-inotersen-hattr\" target=\"_blank\">announcement </a>that has secured an exclusive global license to develop and commercialize Ionis' inotersen and IONIS-TTR-Lrx (AKCEA-TTR-Lrx).</li><li>Inotersen should be approved in the U.S. and EU this summer (FDA action date is July 6) for the treatment of hereditary transthyretin amyloidosis (hATTR).</li><li>ACKEA-TTR-Lrx will be developed for hereditary and wild-type forms of ATTR.</li><li>Under the terms of the agreement, Akcea will pay Ionis an upfront licensing fee of $150M in the form of Akcea shares. Ionis, in return, will purchase $200M of Akcea common stock, upping its ownership stake to 75% from 68%. Regulatory approval of inotersen and AKCEA-TTR-Lrx in the U.S. and EU will trigger milestone payments to Ionis of $50M and $40M, respectively. Ionis will receive additional milestone payments upon approvals in other territories. All may be payable in Akcea stock.</li><li>Commercial profits/losses on inotersen will be split 60/40 between Ionis and Akcea. The split will transition to 50/50 when commercial sales of AKCEA-TTR-Lrx begin. The costs to develop AKCEA-TTR-Lrx and its profits will be equally shared.</li><li>The transaction should close next quarter.</li><li>Ionis Chief Business Officer Sarah Boyce will join Akcea as President and board member.</li></ul><div class=\"tiny-share-widget\" data-id=\"3339547\" data-linked=\"Akcea to commercialize Ionis Pharma&#39;s inotersen; shares up 28%\" data-tweet=\"$IONS $IONS $AKCA - Akcea to commercialize Ionis Pharma&#39;s inotersen; shares up 28% https://seekingalpha.com/news/3339547-akcea-to-commercialize-ionis-pharmas-inotersen-shares-up-28?source=tweet\" data-url=\"https://seekingalpha.com/news/3339547-akcea-to-commercialize-ionis-pharmas-inotersen-shares-up-28\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:47 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>36&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3339546\" data-ts=\"1521124874\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MAXR\" target=\"_blank\">MAXR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3339546-maxarminus-2_5-credit-suisse-cuts-to-neutral\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Maxar -2.5% as Credit Suisse cuts to Neutral</a></h4><ul>   <li>Maxar Technologies (NYSE:<a href='https://seekingalpha.com/symbol/MAXR' title='Maxar Technologies Inc'>MAXR</a>) is <font color='red'>2.5% lower</font> on the NYSE after a downgrade to Neutral at Credit Suisse.</li>    <li>The firm had previously rated Outperform.</li>    <li>Maxar said late last month its CFO William McCombe was stepping down.</li>    <li>Shares are <font color='red'>down 29.5%</font> on NYSE YTD.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3339546\" data-linked=\"Maxar -2.5% as Credit Suisse cuts to Neutral\" data-tweet=\"$MAXR - Maxar -2.5% as Credit Suisse cuts to Neutral https://seekingalpha.com/news/3339546-maxarminus-2_5-credit-suisse-cuts-to-neutral?source=tweet\" data-url=\"https://seekingalpha.com/news/3339546-maxarminus-2_5-credit-suisse-cuts-to-neutral\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:41 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3339540\" data-ts=\"1521124302\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SILC\" target=\"_blank\">SILC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3339540-silicomplus-2_6-on-dividend-suspension\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Silicom +2.6% on dividend suspension</a></h4><ul><li>        Silicom Ltd. (NASDAQ:<a href='https://seekingalpha.com/symbol/SILC' title='Silicom Ltd'>SILC</a>) shares are&nbsp;<font color='green'>up 2.6%</font>&nbsp;as the company <a href=\"https://seekingalpha.com/pr/17103378-silicom-expects-large-vcpe-wins-major-telcos-suspends-dividend-support-long-term-growth-and\" target=\"_blank\">suspends its dividend</a> in the wake of a canceled large customer order.&nbsp;</li><li>        Silicom says it expects to &ldquo;close several major, strategic new SD-WAN and NFV-related vCPE Design Wins from major telcos&rdquo; with the first announcement coming in the &ldquo;near term.&rdquo;</li><li>               Silicom says the significant size of these deals, along with the financial terms and required working capital, led to the dividend suspension to help support long-term growth.&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3338861-silicom-plunges-losing-largest-order\" target=\"_blank\">Silicom plunges after losing largest order</a> (March 13)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3339053-needham-lowers-silicoms-price-target-says-buy-overreaction\" target=\"_blank\">Needham lowers Silicom's price target but says to buy on overreaction</a> (March 14)</li></ul><div class=\"tiny-share-widget\" data-id=\"3339540\" data-linked=\"Silicom +2.6% on dividend suspension\" data-tweet=\"$SILC - Silicom +2.6% on dividend suspension https://seekingalpha.com/news/3339540-silicomplus-2_6-on-dividend-suspension?source=tweet\" data-url=\"https://seekingalpha.com/news/3339540-silicomplus-2_6-on-dividend-suspension\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:31 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3339538\" data-ts=\"1521124006\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ANGI\" target=\"_blank\">ANGI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3339538-angi-homeservicesplus-4-ubs-starts-buy\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ANGI Homeservices +4% as UBS starts at Buy</a></h4><ul>   <li>ANGI Homeservices (NASDAQ:<a href='https://seekingalpha.com/symbol/ANGI' title='ANGI Homeservices Inc.'>ANGI</a>) is <font color='green'>up 4%</font> after an initiation at Buy by UBS.</li>    <li>The firm joins a bullish group of more than a half-dozen Buy recommendations, and set its price target at $20, implying 29% upside from current price.</li>    <li>Shares in <a href='https://seekingalpha.com/symbol/ANGI' title='ANGI Homeservices Inc.'>ANGI</a> are <font color='green'>up 49%</font> YTD.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3339538\" data-linked=\"ANGI Homeservices +4% as UBS starts at Buy\" data-tweet=\"$ANGI - ANGI Homeservices +4% as UBS starts at Buy https://seekingalpha.com/news/3339538-angi-homeservicesplus-4-ubs-starts-buy?source=tweet\" data-url=\"https://seekingalpha.com/news/3339538-angi-homeservicesplus-4-ubs-starts-buy\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:26 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3339534\" data-ts=\"1521123559\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ADAP\" target=\"_blank\">ADAP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3339534-adaptimmunes-ny-eso-spear-t-cells-shows-treatment-effect-in-patients-type-of-soft-tissue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Adaptimmune&#39;s NY-ESO SPEAR T-cells shows treatment effect in patients with type of soft tissue cancer; shares ahead 14%</a></h4><ul><li>Adaptimmune Therapeutics (<a href='https://seekingalpha.com/symbol/ADAP' title='Adaptimmune Therapeutics plc'>ADAP</a> <font color='green'>+13.8%</font>) is up on modestly higher volume in response to its <a href=\"https://seekingalpha.com/pr/17102927-adaptimmune-announces-responses-second-solid-tumor-indication-ny-eso-spear-t-cells\" target=\"_blank\">announcement</a> of positive preliminary results from the first four patients with myxoid/round cell liposarcoma &#40;MRCLS&#41; treated with NY-ESO SPEAR T-cells.</li><li>Three of the four patients experienced partial responses.</li><li>GlaxoSmithKline (<a href='https://seekingalpha.com/symbol/GSK' title='GlaxoSmithKline'>GSK</a> <font color='red'>-0.1%</font>) has exclusive development and commercialization rights. The transition of the program is in process.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3310624-adaptimmunes-ny-eso-spear-t-cell-therapy-shows-encouraging-effect-synovial-sarcoma-pilot\" target=\"_blank\">Adaptimmune's NY-ESO SPEAR T-cell therapy shows encouraging effect in synovial sarcoma pilot study</a> (Nov. 9, 2017)</li></ul><div class=\"tiny-share-widget\" data-id=\"3339534\" data-linked=\"Adaptimmune&#39;s NY-ESO SPEAR T-cells shows treatment effect in patients with type of soft tissue cancer; shares ahead 14%\" data-tweet=\"$ADAP $ADAP $GSK - Adaptimmune&#39;s NY-ESO SPEAR T-cells shows treatment effect in patients with type of soft tissue cancer; shares ahead 14% https://seekingalpha.com/news/3339534-adaptimmunes-ny-eso-spear-t-cells-shows-treatment-effect-in-patients-type-of-soft-tissue?source=tweet\" data-url=\"https://seekingalpha.com/news/3339534-adaptimmunes-ny-eso-spear-t-cells-shows-treatment-effect-in-patients-type-of-soft-tissue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:19 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>33&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3339529\" data-ts=\"1521122793\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IVTY\" target=\"_blank\">IVTY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3339529-invuity-prices-stock-offering-3_50-shares-down-13\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Invuity prices stock offering at $3.50; shares down 13%</a></h4><ul><li>Invuity (<a href='https://seekingalpha.com/symbol/IVTY' title='Invuity'>IVTY</a> <font color='red'>-12.8%</font>) <a href=\"https://seekingalpha.com/pr/17103408-invuity-announces-pricing-public-offering-common-stock\" target=\"_blank\">prices </a>its public offering of 6.2M common shares at $3.50 per share. Underwriters over-allotment is an additional 600K shares. Closing date should about March 19.</li></ul><div class=\"tiny-share-widget\" data-id=\"3339529\" data-linked=\"Invuity prices stock offering at $3.50; shares down 13%\" data-tweet=\"$IVTY - Invuity prices stock offering at $3.50; shares down 13% https://seekingalpha.com/news/3339529-invuity-prices-stock-offering-3_50-shares-down-13?source=tweet\" data-url=\"https://seekingalpha.com/news/3339529-invuity-prices-stock-offering-3_50-shares-down-13\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:06 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3339504\" data-ts=\"1521122519\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GBTC\" target=\"_blank\">GBTC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3339504-crypto-world-continues-decline-death-of-bitcoin-rhetoric-is-back\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Crypto-world continues its decline as the death of Bitcoin rhetoric is back</a></h4><ul><li><a href=\"https://www.bloomberg.com/news/articles/2018-03-14/bitcoin-pop-culture-moment-fades-as-fad-gives-way-to-regulators\" target=\"_blank\">Google searches and tweets</a> about Bitcoin have fallen sharply, as the digital currency continues its decline.</li><li>&ldquo;The general public is now realizing that this is not a risk-free, get-rich-quick, investment opportunity and general interest has since diminished,&rdquo; said Lucas Nuzzi, a senior analyst at Digital Asset Research.</li><li>Bitcoin fell under $8,000 to as low as $7,676 for the first time in a month as <a href=\"https://seekingalpha.com/news/3338956-google-cracks-crypto-advertising\" target=\"_blank\">Google announced a ban</a> in ICO related advertisements.</li><li>Selling from Mt.Gox trustees is blamed as the key reason for the decline in recent months, but regulatory crackdown, and a rising bearish sentiment have also played their part.</li><li>The selling is not limited to Bitcoin as <a href=\"https://www.cnbc.com/2018/03/15/bitcoin-price-over-60-billion-wiped-off-value-of-cryptocurrencies.html\" target=\"_blank\">more than $60B</a> has been wiped off the market value of cryptocurrencies in the past 24 hours, before prices started to recover.</li><li>The biggest tokens by market cap <a href=\"https://www.investing.com/crypto/\" target=\"_blank\">are still down&nbsp;in the last week</a>, with Bitcoin at $8,415&nbsp;<font color='red'>down 16%</font>&nbsp;over the last 7 days, Ethereum at $618 is&nbsp;<font color='red'>down more than 18%</font>, Ripple at $0.70 is&nbsp;<font color='red'>down 18%</font>, and Bitcoin Cash at $939 is&nbsp;<font color='red'>down more than 12%</font>.</li><li>Related Tickers:&nbsp;<a href='https://seekingalpha.com/symbol/GBTC' title='Grayscale Bitcoin Trust &#40;BTC&#41;'>OTCQX:GBTC</a>, <a href='https://seekingalpha.com/symbol/COIN' title='Winklevoss Bitcoin Trust ETF'>COIN</a>, <a href='https://seekingalpha.com/symbol/RIOT' title='Riot Blockchain, Inc.'>RIOT</a>, <a href='https://seekingalpha.com/symbol/OSTK' title='Overstock.com, Inc.'>OSTK</a>, <a href='https://seekingalpha.com/symbol/SSC-OLD' title='Seven Stars Cloud Group, Inc.'>SSC-OLD</a>, <a href='https://seekingalpha.com/symbol/MARA' title='Marathon Patent Group, Inc.'>MARA</a>, <a href='https://seekingalpha.com/symbol/UEPS' title='Net 1 UEPS Technologies, Inc.'>UEPS</a>, <a href='https://seekingalpha.com/symbol/BITCF' title='First Bitcoin Capital Corp.'>OTC:BITCF</a>, <a href='https://seekingalpha.com/symbol/XNET' title='Xunlei Limited'>XNET</a>, <a href='https://seekingalpha.com/symbol/GROW' title='U.S. Global Investors, Inc.'>GROW</a>, <a href='https://seekingalpha.com/symbol/BTSC' title='Bitcoin Services, Inc.'>OTCPK:BTSC</a>, <a href='https://seekingalpha.com/symbol/BTCS' title='BTCS Inc.'>OTCQB:BTCS</a>, <a href='https://seekingalpha.com/symbol/MGTI' title='MGT Capital Investments, Inc.'>OTCQB:MGTI</a>, <a href='https://seekingalpha.com/symbol/BTLLF' title='Interbit Ltd.'>OTCPK:BTLLF</a> <a href='https://seekingalpha.com/symbol/SRAX' title='Social Reality Inc.'>SRAX</a>, <a href='https://seekingalpha.com/symbol/GAHC' title='Global Arena Holding, Inc.'>OTCPK:GAHC</a>, <a href='https://seekingalpha.com/symbol/ARSC' title='American Security Resources Corp.'>OTC:ARSC</a>, <a href='https://seekingalpha.com/symbol/USTC' title='USA Real Estate Holding Co'>OTCPK:USTC</a>, <a href='https://seekingalpha.com/symbol/BLKCF' title='Global Blockchain Technologies Corp.'>OTCPK:BLKCF</a>, <a href='https://seekingalpha.com/symbol/COINB' title='Coinbase'>COINB</a>, <a href='https://seekingalpha.com/symbol/LFIN' title='LongFin Corp.A'>OTCPK:LFIN</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3339504\" data-linked=\"Crypto-world continues its decline as the death of Bitcoin rhetoric is back\" data-tweet=\"$GBTC $GBTC $COIN - Crypto-world continues its decline as the death of Bitcoin rhetoric is back https://seekingalpha.com/news/3339504-crypto-world-continues-decline-death-of-bitcoin-rhetoric-is-back?source=tweet\" data-url=\"https://seekingalpha.com/news/3339504-crypto-world-continues-decline-death-of-bitcoin-rhetoric-is-back\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:01 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>75&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3339519\" data-ts=\"1521122275\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BITA\" target=\"_blank\">BITA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3339519-bitautominus-11_3-after-earnings-downside-revenue-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bitauto -11.3% after earnings with downside revenue guidance</a></h4><ul>   <li>Bitauto (NYSE:<a href='https://seekingalpha.com/symbol/BITA' title='Bitauto Holdings Limited'>BITA</a>) is <font color='red'>11.3% lower</font> in early going after its <a href=\"https://seekingalpha.com/news/3339364-bitauto-beats-0_02-beats-revenue\" target=\"_blank\">Q4 earnings</a> beat high-end estimates but featured Q1 guidance that lagged strong expectations.</li>    <li>Revenues grew by 50% with strong results across segments, and gross profit was up 42% to 1.58B yuan (about $242.7M).</li>    <li>Non-GAAP income from operations shrank to 93.5M yuan ($14.4M) from 140.9M yuan; and non-GAAP net income rose 26% to 99M yuan (about $15.2M).</li>    <li>Revenue by segment: Advertising and subscription, 1.1B yuan (up 18.2%, about $168.9M); Transaction services, 1.27B yuan (up 115.5%, about $195.2M); Digital marketing solutions, 321.9M (up 39.9%, about $49.5M).</li>    <li>For Q1, it's guiding to revenues (ASC 606) of 1.96B-2.01B yuan (up 37.8%-41.3%, about $301.8M-$309.5M, below consensus for $325.6M).</li>    <li><a href=\"https://seekingalpha.com/pr/17102805-bitauto-announces-fourth-quarter-fiscal-year-2017-results\" target=\"_blank\">Press release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3339519\" data-linked=\"Bitauto -11.3% after earnings with downside revenue guidance\" data-tweet=\"$BITA - Bitauto -11.3% after earnings with downside revenue guidance https://seekingalpha.com/news/3339519-bitautominus-11_3-after-earnings-downside-revenue-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3339519-bitautominus-11_3-after-earnings-downside-revenue-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:57 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>16&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3339507\" data-ts=\"1521121002\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WSM\" target=\"_blank\">WSM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3339507-credit-suisse-still-wary-of-williams-sonoma\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Credit Suisse still wary of Williams-Sonoma</a></h4><ul> <li>Credit Suisse is still cautious on Williams-Sonoma (<a href='https://seekingalpha.com/symbol/WSM' title='Williams-Sonoma Inc.'>WSM</a> <font color='green'>+3%</font>) after taking in the retailer's Q4 results.</li> <li>CS post-earnings analysis: \"WSM's sales were better and at the high end of guidance, but still underperformed the industry, while operating profit dollars and margin rate missed guidance and consensus, and were down y/y (the biggest decline since the downturn). Results reflect lower merchandise margins, declining shipping revenue, higher shipping costs, and higher marketing.\"</li> <li>The investment firm lifts its price target on Williams-Sonoma to $48 from $44, due in part to the lower corporate tax rate, but keeps an Underperform rating on the stock.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3339281-strong-guidance-lifts-williams-sonoma\" target=\"_blank\">Strong guidance lifts Williams-Sonoma</a> (March 14)</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3339507\" data-linked=\"Credit Suisse still wary of Williams-Sonoma\" data-tweet=\"$WSM - Credit Suisse still wary of Williams-Sonoma https://seekingalpha.com/news/3339507-credit-suisse-still-wary-of-williams-sonoma?source=tweet\" data-url=\"https://seekingalpha.com/news/3339507-credit-suisse-still-wary-of-williams-sonoma\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:36 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3339506\" data-ts=\"1521120954\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BB\" target=\"_blank\">BB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3339506-chen-to-lead-blackberry-through-2023\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Chen to lead BlackBerry through 2023</a></h4><ul>   <li>BlackBerry (<a href=\"http://seekingalpha.com/symbol/BB\" target=\"_blank\">BB</a> <font color='green'>+1.6%</font>) and Chairman/CEO John Chen have agreed to a <a href=\"https://seekingalpha.com/pr/17103137-blackberry-john-chen-agree-contract-extension\" target=\"_blank\">contract extension through November 2023</a>.</li>    <li>The board has \"tremendous confidence\" in Chen, according to lead director Prem Watsa; \"John engineered a successful turnaround and has the company repositioned to apply its strengths and assets to the Enterprise of Things, an emerging category with massive potential.\"</li>    <li>The new five-year extension is weighted toward long-term performance-based awards and there's no change to Chen's base salary, short-term cash incentive or benefits.</li>    <li>He'll receive a time-based award of 5M restricted share units vesting annually in equal tranches, as well as a performance-based cash award if BlackBerry shares go to $30.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3339506\" data-linked=\"Chen to lead BlackBerry through 2023\" data-tweet=\"$BB - Chen to lead BlackBerry through 2023 https://seekingalpha.com/news/3339506-chen-to-lead-blackberry-through-2023?source=tweet\" data-url=\"https://seekingalpha.com/news/3339506-chen-to-lead-blackberry-through-2023\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:35 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>21&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3339499\" data-ts=\"1521120383\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RUBI\" target=\"_blank\">RUBI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3339499-premarket-gainers-of-9-05-03-15-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Gainers as of 9:05 am (03/15/2018)</a></h4><ul><li><a href='https://seekingalpha.com/symbol/RUBI' title='The Rubicon Project, Inc.'>RUBI</a> <font color='green'>+30%</font>&nbsp;on Q4 <a href=\"https://seekingalpha.com/news/3339236-rubicon-project-eps-line-beats-revenue\" target=\"_blank\">result</a>.</li><li><a href='https://seekingalpha.com/symbol/CWAY' title='Coastway Bancorp, Inc.'>CWAY</a> <font color='green'>+23%</font>.</li><li><a href='https://seekingalpha.com/symbol/PTI' title='Proteostasis Therapeutics'>PTI</a> <font color='green'>+21%&nbsp;</font>on Q4&nbsp;<a href=\"https://seekingalpha.com/news/3339321-proteostasis-therapeutics-reports-q4-results\" target=\"_blank\">result</a>.</li><li><a href='https://seekingalpha.com/symbol/XXII' title='22nd Century Group, Inc.'>XXII</a> <font color='green'>+18%</font>.</li><li>TPIV <font color='green'>+15%</font>&nbsp;as&nbsp;T-cell vaccine candidate TPIV200 <a href=\"https://seekingalpha.com/news/3339486-tapimmunes-t-cell-vaccine-candidate-tpiv200-shows-encouraging-action-early-stage-cancer-study\" target=\"_blank\">shows</a> encouraging action in early-stage cancer study.</li><li><a href='https://seekingalpha.com/symbol/ICON' title='Iconix Brand Group, Inc.'>ICON</a> <font color='green'>+15%</font>&nbsp;on Q4&nbsp;<a href=\"https://seekingalpha.com/news/3339318-iconix-brand-beats-0_07-beats-revenue\" target=\"_blank\">result</a>.</li><li><a href='https://seekingalpha.com/symbol/CHFS' title='CHF Solutions, Inc.'>CHFS</a> <font color='green'>+14%</font>.</li><li><a href='https://seekingalpha.com/symbol/RKDA' title='Arcadia Biosciences'>RKDA</a> <font color='green'>+17%</font>.</li><li><a href='https://seekingalpha.com/symbol/GLMD' title='Galmed Pharmaceuticals Ltd.'>GLMD</a> <font color='green'>+13%</font>.</li><li><a href='https://seekingalpha.com/symbol/ALXN' title='Alexion Pharmaceuticals, Inc.'>ALXN</a> <font color='green'>+10%</font>&nbsp;as long-acting PNH <a href=\"https://seekingalpha.com/news/3339413-alexions-long-acting-pnh-candidate-alxn1210-par-soliris-late-stage-study-shares-11-percent\" target=\"_blank\">candidate ALXN1210</a> on par with Soliris in late-stage study.</li><li><a href='https://seekingalpha.com/symbol/DDD' title='3D Systems Corp.'>DDD</a> <font color='green'>+9%</font>&nbsp;on Q4&nbsp;<a href=\"https://seekingalpha.com/news/3339224-3d-systems-beats-0_05-beats-revenue\" target=\"_blank\">result</a>.</li><li><a href='https://seekingalpha.com/symbol/HMY' title='Harmony Gold Mining Company Limited'>HMY</a> <font color='green'>+9%</font>.</li><li><a href='https://seekingalpha.com/symbol/DG' title='Dollar General Corporation'>DG</a> <font color='green'>+8%</font>&nbsp;on Q4&nbsp;<a href=\"https://seekingalpha.com/news/3339382-dollar-general-eps-line-misses-revenue\" target=\"_blank\">result</a>.</li><li><a href='https://seekingalpha.com/symbol/SMTC' title='Semtech Corporation'>SMTC</a> <font color='green'>+7%</font>&nbsp;on Q4&nbsp;<a href=\"https://seekingalpha.com/news/3339275-semtech-beats-0_01-beats-revenue\" target=\"_blank\">result</a></li><li><a href='https://seekingalpha.com/symbol/ONCS' title='OncoSec Medical Incorporated'>ONCS</a> <font color='green'>+7%</font>&nbsp;as clinical and immunological&nbsp;<a href=\"https://seekingalpha.com/pr/17103036-oncosecs-intratumoral-ilminus-12-metastatic-triple-negative-breast-cancer-tnbc-selected-oral\" target=\"_blank\">data</a> from&nbsp;its OMS-I140 clinical trial of ImmunoPulse IL-12 in patients with metastatic Triple Negative Breast Cancer has been selected as an oral poster presentation at the upcoming American Association of Cancer Research Annual Meeting.</li><li>SHLD <font color='green'>+7%</font>&nbsp;on Q4&nbsp;<a href=\"https://seekingalpha.com/news/3339325-sears-holdings-eps-1_69\" target=\"_blank\">result</a>.</li><li><a href='https://seekingalpha.com/symbol/ABEO' title='Abeona Therapeutics Inc.'>ABEO</a> <font color='green'>+7%</font>&nbsp;as FDA has <a href=\"https://seekingalpha.com/pr/17103199-abeona-therapeutics-receives-fda-rare-pediatric-disease-designation-abominus-202-gene-therapy\" target=\"_blank\">granted</a> Rare Pediatric Disease Designation for the ABO-202 program.</li><li><a href='https://seekingalpha.com/symbol/CLRB' title='Cellectar Biosciences, Inc.'>CLRB</a> <font color='green'>+6%</font>&nbsp;on&nbsp;results from two preclinical studies highlighting the potential benefits of fractionated dosing regimens of CLR 131 and the ability of the company&rsquo;s phospholipid drug conjugates.</li><li><a href='https://seekingalpha.com/symbol/ADT' title='The ADT Corporation'>ADT</a> <font color='green'>+6%</font>&nbsp;on Q4&nbsp;<a href=\"https://seekingalpha.com/news/3339395-adt-misses-0_16-beats-revenue\" target=\"_blank\">result</a></li><li><a href='https://seekingalpha.com/symbol/IDXG' title='Interpace Diagnostics Group, Inc.'>IDXG</a> <font color='green'>+6%</font>.</li><li><a href='https://seekingalpha.com/symbol/APTO' title='Aptose Biosciences Inc.'>APTO</a> <font color='green'>+5%</font>&nbsp;as&nbsp;preclinical data for CG&rsquo;806, its pan-FLT3/pan-BTK inhibitor, and APTO-253, its c-Myc inhibitor, will be presented in three separate posters at the 2018 AACR Annual Meeting.</li><li><a href='https://seekingalpha.com/symbol/LJPC' title='La Jolla Pharmaceutical Co.'>LJPC</a> <font color='green'>+5%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3339449-la-jolla-pharma-prices-stock-offering-29_50-shares-1-percent-premarket\" target=\"_blank\">pricing</a>&nbsp;stock offering at $29.50.</li><li><a href='https://seekingalpha.com/symbol/SVU' title='SUPERVALU Inc.'>SVU</a> <font color='green'>+5%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3339340-supervalu-surges-deal-sell-farm-fresh-stores-43m\" target=\"_blank\">deal</a> to sell Farm Fresh stores for $43M.</li></ul><div class=\"tiny-share-widget\" data-id=\"3339499\" data-linked=\"Premarket Gainers as of 9:05 am (03/15/2018)\" data-tweet=\"$RUBI $RUBI $CWAY - Premarket Gainers as of 9:05 am (03/15/2018) https://seekingalpha.com/news/3339499-premarket-gainers-of-9-05-03-15-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3339499-premarket-gainers-of-9-05-03-15-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:26 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3339487\" data-ts=\"1521119612\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JILL\" target=\"_blank\">JILL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3339487-premarket-losers-of-9-05-3-15-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Losers as of 9:05 am (3/15/2018)</a></h4><ul>     <li><a href='https://seekingalpha.com/symbol/JILL' title='J. Jill Group, Inc.'>JILL</a>&nbsp;<font color='red'>-26%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3339378-j-jill-beats-0_04-beats-revenue\" target=\"_blank\">Q4 earnings</a>.</li><li><a href='https://seekingalpha.com/symbol/SPEX' title='Spherix Incorporated'>SPEX</a> <font color='red'>-18%</font>&nbsp;on <a href=\"https://seekingalpha.com/pr/17102552-spherix-announces-proposed-public-offering-common-stock\" target=\"_blank\">announcing</a> public offering of common stock.</li><li><a href='https://seekingalpha.com/symbol/IVTY' title='Invuity'>IVTY</a> <font color='red'>-16%</font>&nbsp;on&nbsp;<a href=\"https://seekingalpha.com/pr/17102452-invuity-announces-proposed-public-offering-common-stock\" target=\"_blank\">announcing</a>&nbsp;public offering of common stock.</li><li><a href='https://seekingalpha.com/symbol/LTBR' title='Lightbridge Corp'>LTBR</a>&nbsp;<font color='red'>-10%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3339374-lightbridge-reports-q4-results\" target=\"_blank\">Q4 earnings</a>.</li><li><a href='https://seekingalpha.com/symbol/DRD' title='DRDGOLD Limited'>DRD</a> <font color='red'>-9%</font>.</li><li><a href='https://seekingalpha.com/symbol/SEED' title='Origin Agritech Limited'>SEED</a> <font color='red'>-6%</font>.</li><li><a href='https://seekingalpha.com/symbol/ABM' title='ABM Industries Incorporated'>ABM</a>&nbsp;<font color='red'>-6%</font>&nbsp;after announcing a&nbsp;<a href=\"https://seekingalpha.com/news/3339339-abm-industries-minus-1_9-percent-9_05m-share-offering\" target=\"_blank\">secondary offering</a>&nbsp;coming from existing shareholders.</li><li><a href='https://seekingalpha.com/symbol/YTEN' title='Yield10 Bioscience, Inc.'>YTEN</a> <font color='red'>-4%</font>.</li><li><a href='https://seekingalpha.com/symbol/RFIL' title='RF Industries, Ltd.'>RFIL</a> <font color='red'>-4%</font>.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3339487\" data-linked=\"Premarket Losers as of 9:05 am (3/15/2018)\" data-tweet=\"$JILL $JILL $SPEX - Premarket Losers as of 9:05 am (3/15/2018) https://seekingalpha.com/news/3339487-premarket-losers-of-9-05-3-15-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3339487-premarket-losers-of-9-05-3-15-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:13 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3339486\" data-ts=\"1521119229\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MRKR\" target=\"_blank\">MRKR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3339486-tapimmunes-t-cell-vaccine-candidate-tpiv200-shows-encouraging-action-in-early-stage-cancer\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">TapImmune&#39;s T-cell vaccine candidate TPIV200 shows encouraging action in early-stage cancer study; shares ahead 16% premarket</a></h4><ul><li>Thinly traded nano cap TapImmune (TPIV) is up&nbsp;<font color='green'>16%</font>&nbsp;premarket on modestly higher volume in response to its <a href=\"https://seekingalpha.com/pr/17103055-tapimmune-announces-publication-clinical-trial-results-tpiv200-cancer-vaccine-clinical-cancer\" target=\"_blank\">announcement</a> of positive results from a Phase 1 clinical trial assessing T-cell vaccine candidate TPIV200 in patients with ovarian and breast cancer. The data were just published in the journal <em>Clinical Cancer Research.&nbsp;</em></li><li>TPIV200 was well-tolerated by all patients and over 90% developed robust and durable antigen-specific immune responses against a protein called <a href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5239573/\" target=\"_blank\">folate receptor alpha</a> which is overexpressed in a range of cancers. Although the 10-subject trial was not powered for efficacy, the observed median progression-free survival &#40;PFS&#41; was 528 days, significantly above ~313 days for standard-of-care treatment.</li><li>A Phase 2 study in women with platinum-sensitive ovarian cancer is ongoing. Interim data should be available in mid-2019.</li></ul><div class=\"tiny-share-widget\" data-id=\"3339486\" data-linked=\"TapImmune&#39;s T-cell vaccine candidate TPIV200 shows encouraging action in early-stage cancer study; shares ahead 16% premarket\" data-tweet=\"$MRKR - TapImmune&#39;s T-cell vaccine candidate TPIV200 shows encouraging action in early-stage cancer study; shares ahead 16% premarket https://seekingalpha.com/news/3339486-tapimmunes-t-cell-vaccine-candidate-tpiv200-shows-encouraging-action-in-early-stage-cancer?source=tweet\" data-url=\"https://seekingalpha.com/news/3339486-tapimmunes-t-cell-vaccine-candidate-tpiv200-shows-encouraging-action-in-early-stage-cancer\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:07 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3339482\" data-ts=\"1521119061\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HGV\" target=\"_blank\">HGV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3339482-hilton-grand-vacations-prices-secondary-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Hilton Grand Vacations prices secondary offering</a></h4><ul><li>Hilton Grand Vacations (NYSE:<a href='https://seekingalpha.com/symbol/HGV' title='Hilton Grand Vacations Inc.'>HGV</a>) prices a secondary offering of 22.25M shares at $46.25 per share.</li><li>The company also bought 2.5M shares directly from selling shareholder HNA at $44.75 per share as part of its share repurchase program.</li><li>Shares of Hilton Grand Vacations are&nbsp;<font color='red'>down 2.38%</font>&nbsp;premarket to $45.88.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3338998-hilton-grand-vacations-discloses-secondary-offering\" target=\"_blank\">Hilton Grand Vacations discloses secondary offering</a> (March 14)</li></ul><div class=\"tiny-share-widget\" data-id=\"3339482\" data-linked=\"Hilton Grand Vacations prices secondary offering\" data-tweet=\"$HGV - Hilton Grand Vacations prices secondary offering https://seekingalpha.com/news/3339482-hilton-grand-vacations-prices-secondary-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3339482-hilton-grand-vacations-prices-secondary-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:04 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3339476\" data-ts=\"1521118798\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AGEN\" target=\"_blank\">AGEN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3339476-agenus-report-q4-results-shares-down-4-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Agenus report Q4 results; shares down 4% premarket</a></h4><ul><li>Agenus (<a href='https://seekingalpha.com/symbol/AGEN' title='Agenus'>AGEN</a>) <a href=\"https://seekingalpha.com/pr/17103157-agenus-reports-fourth-quarter-full-year-2017-financial-results-provides-corporate-update\" target=\"_blank\">Q4 results</a>: Revenues: $8.4M (+50.0%); Operating Loss: ($30M) (-52.3%); Net Loss: ($35M) (-34.1%); Loss Per Share: ($0.35) (-16.7%); Quick Assets: $60.2M (-21.2%).</li><li><strong>2018 Milestones</strong>: Efficacy data for AGEN 1884 plus Keytruda in 1L NSCLC and planning for BLA filing</li><li>Efficacy data from AGEN1884 (anti-CTLA-4) and AGEN2034 (anti-PD-1) trials.</li><li>Formalize regulatory engagements for the above combos for BLA filing.</li><li>IND filing for next generation CTLA-4 and two undisclosed bispecific antibodies.</li><li>Start combination trial with our CTLA-4 and PD1 with AGEN neoantigen vaccine AutoSynVax.</li><li>Complete IND enabling studies for AgenTus Therapeutics lead adoptive cell therapy program.</li><li><strong>Update on GMP manufacturing</strong>: Expanded and upgraded antibody manufacturing capabilities.</li><li>Produced GMP grade CTLA-4 and PD1 antibodies for our clinical trials and acquired commercial grade AGEN1884 (anti-CTLA-4) and expecting commercial grade AGEN2034 (anti-PD-1) by mid-year.</li><li>Shares are down&nbsp;<font color='red'>4%</font>&nbsp;premarket on light volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3339476\" data-linked=\"Agenus report Q4 results; shares down 4% premarket\" data-tweet=\"$AGEN - Agenus report Q4 results; shares down 4% premarket https://seekingalpha.com/news/3339476-agenus-report-q4-results-shares-down-4-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3339476-agenus-report-q4-results-shares-down-4-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:59 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3339469\" data-ts=\"1521118284\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OVID\" target=\"_blank\">OVID</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3339469-ovids-ov101-fast-trackd-in-u-s-for-fragile-x-syndrome-shares-ahead-11-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ovid&#39;s OV101 Fast Track&#39;d in U.S. for Fragile X syndrome; shares ahead 11% premarket</a></h4><ul><li>Thinly traded micro cap Ovid Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/OVID' title='Ovid Therapeutics Inc.'>OVID</a>) is up&nbsp;<font color='green'>11%</font>&nbsp;premarket on light volume on the heels of its <a href=\"https://seekingalpha.com/pr/17103050-ovid-therapeutics-announces-ov101-granted-fast-track-designation-u-s-fda-treatment-fragile-x\" target=\"_blank\">announcement </a>that the FDA has granted Fast Track status for OV101 for the treatment of Fragile X syndrome, an inherited disorder characterized by learning disabilities and cognitive impairment.</li><li>Fast Track status provides for more frequent interactions with the FDA review team and a rolling review of the marketing application.</li><li>A Phase 2 study in males ages 13 - 22 will commence this year.</li><li><a href=\"http://www.ovidrx.com/our-pipeline/\" target=\"_blank\">OV101</a>&nbsp;(gaboxadol) is a delta (&delta;)-selective GABAA receptor agonist designed to specifically target the disruption of tonic inhibition, a central physiological process of the brain that is believed to be the cause of certain neurodevelopmental disorders.</li></ul><div class=\"tiny-share-widget\" data-id=\"3339469\" data-linked=\"Ovid&#39;s OV101 Fast Track&#39;d in U.S. for Fragile X syndrome; shares ahead 11% premarket\" data-tweet=\"$OVID - Ovid&#39;s OV101 Fast Track&#39;d in U.S. for Fragile X syndrome; shares ahead 11% premarket https://seekingalpha.com/news/3339469-ovids-ov101-fast-trackd-in-u-s-for-fragile-x-syndrome-shares-ahead-11-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3339469-ovids-ov101-fast-trackd-in-u-s-for-fragile-x-syndrome-shares-ahead-11-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:51 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3339467\" data-ts=\"1521118178\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BABA\" target=\"_blank\">BABA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3339467-wsj-alibaba-pursuing-listing-in-mainland-china\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">WSJ: Alibaba pursuing listing in mainland China</a></h4><ul><li>        Alibaba (NYSE:<a href='https://seekingalpha.com/symbol/BABA' title='Alibaba Group Holding Limited'>BABA</a>) is exploring ways to list its shares in mainland China, according to <a href=\"https://www.wsj.com/articles/china-tech-titan-alibaba-plans-stock-market-homecoming-1521116131?mod=rss_Technology\" target=\"_blank\">WSJ sources</a>.</li><li>               The secondary listing could happen as soon as this summer if China&rsquo;s securities rules change to allow foreign companies to list. Alibaba&rsquo;s key business is in China, but the company is incorporated in the Cayman Islands.&nbsp;</li><li>               WSJ previously reported that China&rsquo;s securities regulator has spoken with investment banks about allowing foreign companies to issue securities on the mainland.&nbsp;</li><li>               For Alibaba, the dual listing would give the option of domestic fundraising in local currency.&nbsp;</li><li>               Alibaba&rsquo;s 2014 listing on the NYSE still stands as the world&rsquo;s largest IPO with its $25B float.&nbsp;</li><li>               Alibaba shares are&nbsp;<font color='green'>up 4.2%</font>&nbsp;premarket to $200.55.&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3338780-alibaba-participates-866m-round-bike-sharing-company\" target=\"_blank\">Alibaba participates in $866M round for bike-sharing company</a> (March 13)</li></ul><div class=\"tiny-share-widget\" data-id=\"3339467\" data-linked=\"WSJ: Alibaba pursuing listing in mainland China\" data-tweet=\"$BABA - WSJ: Alibaba pursuing listing in mainland China https://seekingalpha.com/news/3339467-wsj-alibaba-pursuing-listing-in-mainland-china?source=tweet\" data-url=\"https://seekingalpha.com/news/3339467-wsj-alibaba-pursuing-listing-in-mainland-china\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:49 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>90&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3339463\" data-ts=\"1521117735\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ZBH\" target=\"_blank\">ZBH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3339463-premarket-analyst-action-healthcare\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket analyst action - healthcare</a></h4><ul><li>Zimmer Biomet Holdings (NYSE:<a href='https://seekingalpha.com/symbol/ZBH' title='Zimmer Biomet Holdings, Inc.'>ZBH</a>) initiated with Outperform rating at Raymond James. Shares are up a fraction premarket.</li><li>Stryker (NYSE:<a href='https://seekingalpha.com/symbol/SYK' title='Stryker Corporation'>SYK</a>) initiated with Outperform rating at Raymond James. Shares up a fraction premarket.</li><li>GalMed Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/GLMD' title='Galmed Pharmaceuticals Ltd.'>GLMD</a>) upgraded to Buy with a $14 (126% upside) price target at Maxim Group. Shares up&nbsp;<font color='green'>12%</font>&nbsp;premarket.</li><li>Akcea Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/AKCA' title='Akcea Therapeutics'>AKCA</a>) upgraded to Outperform at Wells Fargo. Shares up&nbsp;<font color='green'>6%</font>&nbsp;premarket.</li><li>LIfePoint Health (NASDAQ:<a href='https://seekingalpha.com/symbol/LPNT' title='LifePoint Health, Inc.'>LPNT</a>) upgraded to Outperform at Raymond James.</li><li>Solid Biosciences (NASDAQ:<a href='https://seekingalpha.com/symbol/SLDB' title='Solid Biosciences, Inc.'>SLDB</a>) downgraded to Underweight at JPMorgan. Shares down&nbsp;<font color='red'>59%&nbsp;</font>premarket on clinical hold of key study.</li><li>Teladoc (NYSE:<a href='https://seekingalpha.com/symbol/TDOC' title='Teladoc Health, Inc.'>TDOC</a>) downgraded to Hold at Deutsche Bank.</li></ul><div class=\"tiny-share-widget\" data-id=\"3339463\" data-linked=\"Premarket analyst action - healthcare\" data-tweet=\"$ZBH $ZBH $SYK - Premarket analyst action - healthcare https://seekingalpha.com/news/3339463-premarket-analyst-action-healthcare?source=tweet\" data-url=\"https://seekingalpha.com/news/3339463-premarket-analyst-action-healthcare\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:42 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3339454\" data-ts=\"1521117057\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SMRT\" target=\"_blank\">SMRT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3339454-stein-mart-pops-after-earnings-credit-transaction\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Stein Mart pops after earnings, credit transaction</a></h4><ul> <li>Stein Mart (NASDAQ:<a href='https://seekingalpha.com/symbol/SMRT' title='Stein Mart, Inc.'>SMRT</a>) announces that it closed on a new $50M term loan.</li><li>The company says it amended its credit agreement with Wells Fargo to provide for the repayment of the existing $25M first-in, last-out&nbsp; A-1 tranche of the credit facility. All other key terms of the Credit Facility remain unchanged.</li>   <li>CFO update: \"This transaction will provide us with additional liquidity bringing our cash and unused borrowing availability today to more than $60 million. This shows the confidence that our lending partners have in our business.\"</li><li>SMRT  <font color='green'>+65%</font> premarket to  $1.27.</li><li>Source: <a href=\"https://seekingalpha.com/pr/17102473-stein-mart-closes-new-50-million-term-loan\" target=\"_blank\">Press Release</a></li><li>Previously: <a href=\"https://seekingalpha.com/news/3339245-stein-mart-reports-q4-results\" target=\"_blank\">Stein Mart reports Q4 results</a> (March 14)</li></ul><div class=\"tiny-share-widget\" data-id=\"3339454\" data-linked=\"Stein Mart pops after earnings, credit transaction\" data-tweet=\"$SMRT - Stein Mart pops after earnings, credit transaction https://seekingalpha.com/news/3339454-stein-mart-pops-after-earnings-credit-transaction?source=tweet\" data-url=\"https://seekingalpha.com/news/3339454-stein-mart-pops-after-earnings-credit-transaction\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:30 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3339452\" data-ts=\"1521117009\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NEOS\" target=\"_blank\">NEOS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3339452-neos-therapeutics-revenues-up-126-in-q4\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Neos Therapeutics revenues up 126% in Q4</a></h4><ul><li>Neos Therapeutics (<a href='https://seekingalpha.com/symbol/NEOS' title='Neos Therapeutics'>NEOS</a> <font color='green'>+1.1%</font>) <a href=\"https://seekingalpha.com/pr/17102871-neos-therapeutics-reports-fourth-quarter-full-year-2017-financial-results\" target=\"_blank\">Q4 results</a>: Revenues: $7.9M (+125.7%); Operating Loss: ($11.7M) (+30.4%); Net Loss: ($14.2M) (+22.8%); Loss Per Share: ($0.49) (+57.0%); Quick Assets: $50.4M (+26.6%).</li><li>No guidance given.</li><li>Shares are up&nbsp;<font color='green'>3%</font>&nbsp;premarket.</li></ul><div class=\"tiny-share-widget\" data-id=\"3339452\" data-linked=\"Neos Therapeutics revenues up 126% in Q4\" data-tweet=\"$NEOS - Neos Therapeutics revenues up 126% in Q4 https://seekingalpha.com/news/3339452-neos-therapeutics-revenues-up-126-in-q4?source=tweet\" data-url=\"https://seekingalpha.com/news/3339452-neos-therapeutics-revenues-up-126-in-q4\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:30 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3339449\" data-ts=\"1521116582\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LJPC\" target=\"_blank\">LJPC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3339449-la-jolla-pharma-prices-stock-offering-29_50-shares-up-1-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">La Jolla Pharma prices stock offering at $29.50; shares up 1% premarket</a></h4><ul><li>La Jolla Pharmaceutical (NASDAQ:<a href='https://seekingalpha.com/symbol/LJPC' title='La Jolla Pharmaceutical Co.'>LJPC</a>) <a href=\"https://seekingalpha.com/pr/17103037-la-jolla-pharmaceutical-company-announces-pricing-public-offering-common-stock\" target=\"_blank\">prices </a>its public offering of 3.4M shares of common stock at $29.50 per share. Underwriters over-allotment is an additional 510K shares. Closing date is March 19.</li><li>Yesterday's close was $29.84. Shares are up&nbsp;<font color='green'>1%</font>&nbsp;premarket on light volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3339449\" data-linked=\"La Jolla Pharma prices stock offering at $29.50; shares up 1% premarket\" data-tweet=\"$LJPC - La Jolla Pharma prices stock offering at $29.50; shares up 1% premarket https://seekingalpha.com/news/3339449-la-jolla-pharma-prices-stock-offering-29_50-shares-up-1-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3339449-la-jolla-pharma-prices-stock-offering-29_50-shares-up-1-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:23 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3339448\" data-ts=\"1521116228\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GCO\" target=\"_blank\">GCO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3339448-on-genescos-q4-beat\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">More on Genesco&#39;s Q4 beat</a></h4><ul><li>Genesco (NYSE:<a href='https://seekingalpha.com/symbol/GCO' title='Genesco Inc.'>GCO</a>)&nbsp;reports&nbsp;comparable sales rose 1% in <a href=\"https://seekingalpha.com/pr/17102843-genesco-reports-fourth-quarter-fiscal-2018-results\" target=\"_blank\">Q4</a>.</li><li>Segment comp growth :&nbsp;Journeys Group +11%,&nbsp;Schuh Group +1%,&nbsp;Lids Sports Group -14%,&nbsp;Johnston &amp; Murphy Group&nbsp;+4%.</li><li>Segment sales:&nbsp;Journeys Group: $452.88M&nbsp;(+15.8%);&nbsp;Schuh Group: $128.13M&nbsp;(+16.3%);&nbsp;Lids Sports Group: $240.99M (-13.6%);&nbsp;Johnston &amp; Murphy Group: $92.38M&nbsp;(+12.5%);&nbsp;&nbsp;Licensed Brands: $15.89M (-23.4%).</li><li>E-commerce sales rose 15% Y/Y.</li><li>Gross margin rate fell 40 bps to 46.9%.</li><li>SG&amp;A expense rate up 50 bps to 40.2%.</li><li>Adjusted operating margin rate slipped 80 bps to 6.8%.</li><li>Total retail units -100 Y/Y to 2,694.</li><li><b>FY2019 Guidance</b>: Comparable sales: flat to +2%; Adjusted EPS: $3.05 to $3.45; Tax rate: ~26.8%.</li></ul><div class=\"tiny-share-widget\" data-id=\"3339448\" data-linked=\"More on Genesco&#39;s Q4 beat\" data-tweet=\"$GCO - More on Genesco&#39;s Q4 beat https://seekingalpha.com/news/3339448-on-genescos-q4-beat?source=tweet\" data-url=\"https://seekingalpha.com/news/3339448-on-genescos-q4-beat\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:17 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3339437\" data-ts=\"1521115485\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MTCH\" target=\"_blank\">MTCH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3339437-ubs-downgrades-match-group-raises-price-target\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">UBS downgrades Match Group, raises price target</a></h4><ul><li>        UBS downgrades Match Group (NASDAQ:<a href='https://seekingalpha.com/symbol/MTCH' title='Match Group, Inc.'>MTCH</a>) from Buy to Neutral.</li><li>               Firm raises its price target from $42 to $48, a nearly 3% upside to yesterday&rsquo;s close.&nbsp;</li><li>               Source: Briefing.com.&nbsp;</li><li>                  Match Group shares are&nbsp;<font color='red'>down 1.3%</font>&nbsp;premarket to $46.17.&nbsp;&nbsp;&nbsp; </li></ul><div class=\"tiny-share-widget\" data-id=\"3339437\" data-linked=\"UBS downgrades Match Group, raises price target\" data-tweet=\"$MTCH - UBS downgrades Match Group, raises price target https://seekingalpha.com/news/3339437-ubs-downgrades-match-group-raises-price-target?source=tweet\" data-url=\"https://seekingalpha.com/news/3339437-ubs-downgrades-match-group-raises-price-target\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:04 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3339436\" data-ts=\"1521115481\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BKS\" target=\"_blank\">BKS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3339436-barnes-noble-shoots-higher-after-guidance-update\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Barnes &amp; Noble shoots higher after guidance update</a></h4><ul> <li>Barnes &amp; Noble (NYSE:<a href='https://seekingalpha.com/symbol/BKS' title='Barnes & Noble Inc'>BKS</a>) says it expects EBITDA in 2019 of $175M to $200M. The outlook is much higher than the consensus estimate of analysts of $145M.</li> <li>B&amp;N expects fiscal 2019 EBITDA to grow through improved sales trends and expense reductions.</li> <li>The retailer plans to post more information on full-year guidance when it reports FY18 results on or around June 21.</li> <li>SEC Form 8-K</li> <li>Shares of Barnes and Noble are&nbsp;<font color='green'>up 10.42%</font>&nbsp;premarket to $5.30.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3339436\" data-linked=\"Barnes &amp; Noble shoots higher after guidance update\" data-tweet=\"$BKS - Barnes &amp; Noble shoots higher after guidance update https://seekingalpha.com/news/3339436-barnes-noble-shoots-higher-after-guidance-update?source=tweet\" data-url=\"https://seekingalpha.com/news/3339436-barnes-noble-shoots-higher-after-guidance-update\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:04 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3339432\" data-ts=\"1521115263\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SLDB\" target=\"_blank\">SLDB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3339432-fda-places-solid-biosciences-dmd-study-of-lead-candidate-sgtminus-001-on-clinical-hold-due-to\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA places Solid Biosciences&#39; DMD study of lead candidate SGT-001 on clinical hold due to adverse event in first patient; shares down 57% premarket</a></h4><ul><li>Recent IPO Solid Biosciences (NASDAQ:<a href='https://seekingalpha.com/symbol/SLDB' title='Solid Biosciences, Inc.'>SLDB</a>) slumps&nbsp;<font color='red'>57%&nbsp;</font>premarket on average volume in response to its <a href=\"https://seekingalpha.com/pr/17102569-solid-biosciences-announces-clinical-hold-sgtminus-001-phase-ii-clinical-trial-duchenne\" target=\"_blank\">announcement </a>that the FDA has placed its Phase 1/2 clinical trial assessing SGT-001 in patients with Duchenne muscular dystrophy &#40;DMD&#41; on clinical hold.</li><li>The agency took action after the first patient dosed experienced a Suspected Unexpected Serious Adverse Reaction &#40;SUSAR&#41;. Specifically, several days after the patient, a non-ambulatory adolescent, received 5E13 vg/kg of SGT-001 he was hospitalized due to a decrease on platelet count followed by a reduction in red blood cell count and evidence of complement activation. He showed no signs of a bleeding disorder called coagulopathy (prolonged/excessive bleeding) and no relevant changes from baseline in liver function tests. The company says he responded well to treatment and is currently asymptomatic. All laboratory parameters have either improved or returned to normal and he is being followed on an outpatient basis.</li><li>The company says it will work closely with the FDA to resolve the issue once it receives the formal Clinical Hold letter which will describe the requirements for resuming the study.</li><li>Rare Pediatric Disease- and Orphan Drug-tagged SGT-001 is an adeno-associated &#40;AAV&#41; vector-mediated gene transfer designed to deliver a synthetic dystrophin gene called microdystrophin to the body, thereby addressing the underlying cause of DMD.</li><li>DMD-related tickers: (NASDAQ:<a href='https://seekingalpha.com/symbol/SRPT' title='Sarepta Therapeutics, Inc.'>SRPT</a>)(NASDAQ:<a href='https://seekingalpha.com/symbol/WVE' title='Wave Life Sciences'>WVE</a>)(NASDAQ:<a href='https://seekingalpha.com/symbol/CATB' title='Catabasis Pharmaceuticals'>CATB</a>)(NASDAQ:<a href='https://seekingalpha.com/symbol/CAPR' title='Capricor Therapeutics, Inc.'>CAPR</a>)(NASDAQ:<a href='https://seekingalpha.com/symbol/SMMT' title='Summit Therapeutics'>SMMT</a>)</li></ul><div class=\"tiny-share-widget\" data-id=\"3339432\" data-linked=\"FDA places Solid Biosciences&#39; DMD study of lead candidate SGT-001 on clinical hold due to adverse event in first patient; shares down 57% premarket\" data-tweet=\"$SLDB $SLDB $SRPT - FDA places Solid Biosciences&#39; DMD study of lead candidate SGT-001 on clinical hold due to adverse event in first patient; shares down 57% premarket https://seekingalpha.com/news/3339432-fda-places-solid-biosciences-dmd-study-of-lead-candidate-sgtminus-001-on-clinical-hold-due-to?source=tweet\" data-url=\"https://seekingalpha.com/news/3339432-fda-places-solid-biosciences-dmd-study-of-lead-candidate-sgtminus-001-on-clinical-hold-due-to\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:01 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3339429\" data-ts=\"1521115154\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/QRVO\" target=\"_blank\">QRVO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3339429-bofaml-downgrades-qorvo-to-3-downside\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BofAML downgrades Qorvo to 3% downside</a></h4><ul><li>        Bank of America Merrill Lynch <a href=\"https://www.streetinsider.com/Analyst+PT+Change/BofAMerrill+Lynch+Downgrades+Qorvo+Inc+%28QRVO%29+to+Underperform+Citing+Limited+UpsideIncreased+Competition/13946525.html\" target=\"_blank\">downgrades</a> Qorvo (NASDAQ:<a href='https://seekingalpha.com/symbol/QRVO' title='Qorvo, Inc'>QRVO</a>) from Neutral to Underperform.</li><li>               Firm lowers the price target from $85 to $80, a 3% downside to yesterday&rsquo;s close.&nbsp;&nbsp;</li><li>               Qorvo shares are&nbsp;<font color='red'>down 1.7%</font>&nbsp;premarket to $80.79.&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3339429\" data-linked=\"BofAML downgrades Qorvo to 3% downside\" data-tweet=\"$QRVO - BofAML downgrades Qorvo to 3% downside https://seekingalpha.com/news/3339429-bofaml-downgrades-qorvo-to-3-downside?source=tweet\" data-url=\"https://seekingalpha.com/news/3339429-bofaml-downgrades-qorvo-to-3-downside\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:59 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3339421\" data-ts=\"1521113964\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AAPL\" target=\"_blank\">AAPL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3339421-eu-sets-date-for-apple-shazam-approval-apple-supplier-denies-production-shutdown\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">EU sets date for Apple-Shazam approval; Apple supplier denies production shutdown</a></h4><ul><li>        EU antitrust regulators will <a href=\"https://www.reuters.com/article/us-shazam-m-a-apple-eu/eu-antitrust-regulators-to-decide-on-apple-shazam-deal-by-april-23-idUSKCN1GR1C4\" target=\"_blank\">decide by April 23</a> whether to approve Apple&rsquo;s (NASDAQ:<a href='https://seekingalpha.com/symbol/AAPL' title='Apple Inc.'>AAPL</a>) acquisition of music app Shazam.</li><li>                  Apple filed for approval yesterday. Seven European countries had previously asked the European Commission to oversee the case.    </li><li>               Supplier issue: Chinese news site Commercial Times claims iPhone supplier Wistron was <a href=\"https://9to5mac.com/2018/03/15/wistron-unauthorized-components-denial/\" target=\"_blank\">using &ldquo;unauthorized components&rdquo;</a> during the production of the iPhone 8 Plus. The news site says Apple ordered a production halt when it found out and production was down for two weeks.&nbsp;</li><li>               Wistron&rsquo;s statement to Digitimes on the matter says it doesn&rsquo;t comment on &ldquo;matters concerning specific clients&rdquo; and denies a two-week production suspension. But the statement doesn&rsquo;t outright deny the production issue.&nbsp;</li><li>               The issue, if it existed, was at Wistron&rsquo;s Chinese operations, where the company is a secondary supplier behind Foxconn. Wistron does serve as the primary iPhone assembler in India. &nbsp;&nbsp;</li><li>Apple shares are&nbsp;<font color='red'>down 0.1%</font>&nbsp;to $178.30.&nbsp; &nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3339134-former-apple-employees-discuss-siri-problems-information\" target=\"_blank\">Former Apple employees discuss Siri problems with The Information</a> (March 14)</li></ul><div class=\"tiny-share-widget\" data-id=\"3339421\" data-linked=\"EU sets date for Apple-Shazam approval; Apple supplier denies production shutdown\" data-tweet=\"$AAPL - EU sets date for Apple-Shazam approval; Apple supplier denies production shutdown https://seekingalpha.com/news/3339421-eu-sets-date-for-apple-shazam-approval-apple-supplier-denies-production-shutdown?source=tweet\" data-url=\"https://seekingalpha.com/news/3339421-eu-sets-date-for-apple-shazam-approval-apple-supplier-denies-production-shutdown\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:39 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3339415\" data-ts=\"1521113479\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TLRD\" target=\"_blank\">TLRD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3339415-tailored-brands-rallies-after-improved-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tailored Brands rallies after improved results</a></h4><ul> <li>Shares of Tailored Brands (NYSE:<a href='https://seekingalpha.com/symbol/TLRD' title='Tailored Brands, Inc'>TLRD</a>) break higher after the retailer bests <a href=\"https://seekingalpha.com/news/3339293-tailored-brands-beats-0_11-beats-revenue\" target=\"_blank\">Q4</a> estimates by a comfortable margin and sets solid guidance.</li> <li>Tailored Brands expects comparable sales for Men's Wearhouse and Jos. A. Bank businesses to be up at a low-single-digit rate, Moores comparable sales to be flat-to-up slightly and K&amp;G comparable sales to be flat-to-down slightly. EPS is seen falling in a range of $2.35 to $2.50 vs. $2.29 consensus.</li> <li>CEO outlook: \"We believe Tailored Brands is the largest and fastest growing retailer of men's custom clothing in North America and we plan to further enhance and differentiate our custom offering in 2018. We also significantly strengthened our balance sheet, reducing debt by approximately $200 million and lowering inventories by 11%.  In 2018, we plan to further reduce our debt, invest behind our growth strategies and return cash to shareholders via our dividend.\"</li> <li>TLRD&nbsp;<font color='green'>+5.56%</font>&nbsp;premarket to $24.50 vs. a 52-week trading range of $9.40 to $26.03.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3339415\" data-linked=\"Tailored Brands rallies after improved results\" data-tweet=\"$TLRD - Tailored Brands rallies after improved results https://seekingalpha.com/news/3339415-tailored-brands-rallies-after-improved-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3339415-tailored-brands-rallies-after-improved-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:31 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3339414\" data-ts=\"1521113470\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JILL\" target=\"_blank\">JILL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3339414-j-jill-beats-q4-estimates\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">J.Jill beats Q4 estimates</a></h4><ul><li>J. Jill (NYSE:<a href='https://seekingalpha.com/symbol/JILL' title='J. Jill Group, Inc.'>JILL</a>) reports comparable sales growth of 8.9% in <a href=\"https://seekingalpha.com/pr/17102840-j-jill-inc-announces-fourth-quarter-fiscal-year-2017-results\" target=\"_blank\">Q4</a>.</li><li>Direct to consumer sales represented 46.6% of sales vs. 48.8% a year ago.</li><li>Gross margin rate dropped 100 bps to 62.2%.</li><li>SG&amp;A expense rate leveraged 20 bps to 54.8%.</li><li>Adjusted EBITDA margin rate down 70 bps to 12.8%.</li><li>Operating margin rate fell 30 bps to 6.2%.</li><li><strong>Q1 Guidance</strong>: Total comparable sales: To decrease in the mid-single digit range; Diluted EPS: $0.18 to $0.20; Tax rate: ~26%.</li></ul><div class=\"tiny-share-widget\" data-id=\"3339414\" data-linked=\"J.Jill beats Q4 estimates\" data-tweet=\"$JILL - J.Jill beats Q4 estimates https://seekingalpha.com/news/3339414-j-jill-beats-q4-estimates?source=tweet\" data-url=\"https://seekingalpha.com/news/3339414-j-jill-beats-q4-estimates\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:31 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3339413\" data-ts=\"1521113455\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ALXN\" target=\"_blank\">ALXN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3339413-alexions-long-acting-pnh-candidate-alxn1210-on-par-soliris-in-late-stage-study-shares-up-11\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Alexion&#39;s long-acting PNH candidate ALXN1210 on par with Soliris in late-stage study; shares up 11% premarket</a></h4><ul><li>Alexion Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/ALXN' title='Alexion Pharmaceuticals, Inc.'>ALXN</a>) is up&nbsp;<font color='green'>11%</font>&nbsp;premarket on light volume in response to its <a href=\"https://seekingalpha.com/pr/17102830-alexion-announces-positive-top-line-results-showing-successful-phase-3-clinical-study\" target=\"_blank\">announcement </a>of successful results from a Phase 3 clinical trial assessing ALXN1210 in patients with paroxysmal nocturnal hemoglobinuria &#40;PNH&#41;.</li><li>The data showed ALXN1210 to be non-inferior to Soliris (eculizumab) by virtue of achieving the co-primary endpoints of transfusion avoidance and normalization of lactate dehydrogenase &#40;LDH&#41; levels, a direct marker of complement-mediated hemolysis in PNH.</li><li>ALXN1210 also demonstrated non-inferiority to Soliris on all four key secondary endpoints.</li><li>Detailed results will be submitted for presentation at a future medical conference.</li><li>ALXN1210 is a long-acting C5 inhibitor that is administered six times per year compared to 26 times per year for Soliris.</li><li>The company plans to file marketing applications in the U.S., EU and Japan in H2.</li><li>Management will host a conference call this morning at 8:30 am ET to discuss the results.</li><li>PNH-related tickers: (NASDAQ:<a href='https://seekingalpha.com/symbol/APLS' title='Apellis Pharmaceuticals, Inc.'>APLS</a>)(NASDAQ:<a href='https://seekingalpha.com/symbol/RARX' title='Ra Pharmaceuticals'>RARX</a>)(NASDAQ:<a href='https://seekingalpha.com/symbol/AKTX' title='Akari Therapeutics Plc'>AKTX</a>)(NASDAQ:<a href='https://seekingalpha.com/symbol/ACHN' title='Achillion Pharmaceuticals, Inc.'>ACHN</a>)(NASDAQ:<a href='https://seekingalpha.com/symbol/FBIO' title='Fortress Biotech, Inc.'>FBIO</a>)</li></ul><div class=\"tiny-share-widget\" data-id=\"3339413\" data-linked=\"Alexion&#39;s long-acting PNH candidate ALXN1210 on par with Soliris in late-stage study; shares up 11% premarket\" data-tweet=\"$ALXN $ALXN $APLS - Alexion&#39;s long-acting PNH candidate ALXN1210 on par with Soliris in late-stage study; shares up 11% premarket https://seekingalpha.com/news/3339413-alexions-long-acting-pnh-candidate-alxn1210-on-par-soliris-in-late-stage-study-shares-up-11?source=tweet\" data-url=\"https://seekingalpha.com/news/3339413-alexions-long-acting-pnh-candidate-alxn1210-on-par-soliris-in-late-stage-study-shares-up-11\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:30 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>18&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li>","count":75,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}